

CEDARS-SINAI MEDICAL CENTER
Los Angeles, California

CURRICULUM VITAE

Name: Shlomo Melmed MB ChB FRCP MACP

Position: Executive Vice President, Academic Affairs
Dean, Medical Faculty

Office Address: Cedars-Sinai Medical Center
8700 Beverly Blvd., 2015
Los Angeles, CA 90048
Tel (310) 423-4691, Fax (310) 423-0119
E-mail: melmed@csmc.edu
Web: <https://www.cedars-sinai.edu/research/labs/melmed.html>

Clinic: Pituitary Center
AHSP 127 S. San Vicente, 6th Floor
Tel 310 423-2830
Fax (310) 423-2819

Place of Birth Cape Town, South Africa
Citizenship U.S.A.

MEDICAL EDUCATION

1965 - 1970 University of Cape Town School of Medicine, South Africa
Received Degree M.B. Ch.B with Distinction; Gold Medal in Medicine and Pediatrics

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS

1971 - 1977 Resident, Internal Medicine and Endocrinology, Sheba Medical Ctr, Israel
1978 - 1980 Endocrinology Research Fellow, Wadsworth VA, UCLA School of Medicine

LICENSURE AND SPECIALTY CERTIFICATIONS

2023 California Medical State License #A34247
1979 Diplomate: American Board of Internal Medicine
1983 Diplomate: Endocrinology & Metabolism Subspecialty

FACULTY APPOINTMENTS

Cedars-Sinai Medical Center, Los Angeles, CA:

1998 - Current Dean of the Medical Faculty & Executive Vice President
2020 - Current Distinguished Professor of Medicine
1998 - Current Chief Academic Officer
1992 - 2020 Director, Research Institute
1986 - 1998 Director, Division of Endocrinology & Metabolism
1988 - 1991 Associate Director, Cedars-Sinai Research Institute
1983 - 1986 Associate Director, Division of Endocrinology
1967 Laboratory Instructor, Dept. Physiology, University of Cape Town

University of California at Los Angeles, School of Medicine:

1998 - Current Associate Dean
1988 - Current Professor of Medicine
1984 - 1988 Associate Professor of Medicine
1980 - 1984 Assistant Professor of Medicine
1979 - 1980 Visiting Assistant Professor of Medicine

PROFESSIONAL ACTIVITIES

Editorial

1998 - 2012 *Editor-in-Chief:* Endocrine Updates
1992 - 1997 *Editor-in-Chief* Endocrinology
1990 - 1992 *Editor* Endocrinology
2010 - 2014 *Editor (Endocrine)* Encyclopedia of Human Biology
1992 - Current *Consulting Editor* Journal of Clinical Investigation
1998 - Current *Editor-in-Chief* Pituitary
2022 - Current *Senior Editor* eLIFE

Editorial Board

1984 - 1988 Endocrinology
1998 - 2001 Journal Clinical Endocrinology & Metabolism
2003 - 2006 Endocrine Reviews
2005 - 2010 Nature Clinical Practice Endocrinology and Metab
1989 Endocrine Pathology
2011 - 2012 Journal of Endocrinology and Journal of Molecular Endocrinology
2002 - 2010 Endocrine-Related Cancer
1999 - Current Best Practice & Research in Clinical Endocrinology and Metabolism
2010 - Current Nature Reviews Endocrinology
2018 - Current Current Opinion in Endocrine and Metabolic Research

REVIEWER Journal of Biological Chemistry; Journal of Clinical Endocrinology and Metabolism; Molecular Endocrinology, Nature, New England Journal of Medicine; PNAS; Nature Medicine, Science; Annals of Internal Medicine; JAMA, Nature Reviews Endocrinology; Nature Reviews Cancer

GRANT REVIEWER

1988-1991,1996-2000 NIH, Endocrinology, Biomedical Sciences and NIDDK Study Sections

2009-2020 NIH ad hoc

1996- 2000 NIH, Chair, Special Endocrinology Study Sections.
Wellcome Foundation & Medical Research Council, UK;
National Science Foundation; VA Merit Review; American Diabetes Assoc;
Ares-Serono Fdtn; French, Belgian, Italian, EU National Research Agencies

SERVICE

Cedars-Sinai Health System

Executive Committee of the Board 1998 - Current
President's Executive Advisory Committee 1998 - Current
Executive Management Group 1998 - Current
Resource Development Committee 1998 - Current
Community Benefit Committee 2000 - 2001
Quality Assurance Executive Committee 1986 - 1989

Medicine Advisory Committee	1986 - 1998
Housestaff Clinical Competency Committee	1986 - 1995
Strategic Planning Task Force	1990 - Current
Medical Leadership Group (Chair)	1998 - Current
<u><i>UCLA School of Medicine</i></u>	
Appointments and Promotions Committee Department of Medicine	1986 - 1993
Committee on Education in the Medical Sciences	1989 - 1991
Legislative Assembly, UCLA Academic Senate	1987 - 1989
Search Committee, Brain Research Institute	1988
NICHD Population Research Center, Executive Committee	1987 - 1991
Committee on Endocrinology Curriculum Planning	1990 - 1992
Advisory Board, Center for Neurovisceral Sciences and Women's Health	2002 - 2007
Deans Education Council	1999 - Current
Task Force for LCME Accreditation	2004 - Current
CTSI Steering Committee	2011 - Current
<u><i>American Diabetes Association</i></u>	
Research Peer Review Committee-California, Chair	1983 - 1990
<u><i>American Thyroid Association</i></u>	
Program Committee	1988
Finance and Audit Committee (Chair)	1988 - 1989
<u><i>Endocrine Society</i></u>	
Council	1999 - 2003
Clinical Endocrinology Initiatives Committee	1988 - 1989
Postgraduate Committee	1990 - 1992
Subcommittee for Introduction to Endocrine Investigation Course	1990 - 1992
Journals Steering & Publications Committee	1992 - 1997
Program Committee, Postgraduate Assembly	1995
Review Committee for Travel Grants	1995; 2008
Planning Committee, Clinical Endocrinology Update	1999
Chair, Central Committee, (ISE) Endocrine Society	2000 - 2008
Self-Assessment Program on CD-ROM (Pituitary Faculty)	1998
Clinical Guidelines Subcommittee	2007 - 2010
Endocrine Society Guideline Task Forces Member	2011 - 2017
<u><i>International Society of Endocrinology</i></u>	
Central Committee, Int'l Society of Endocrinology	1996 - 2004
Program Committee, International Congress of Endocrinology	2000
Chair, Program Committee, International Congress of Endocrinology	2004
President, International Society of Endocrinology	2004 - 2008
Co-Chair, International Congress of Endocrinology	2018
<u><i>AFCR/ASCI/AAP</i></u>	
Western Society Clinical Investigation, Endocrinology Coordinator	1985, 1987
Endocrinology and Metabolism Chairman, (AFCR/ASCI/AAP)	1985, 1989, 1991
Nominating Committee, WAP	1992
<u><i>Los Angeles Cross-Town Endocrine Society</i></u>	
Chairperson	1984 - 1985
<u><i>Pituitary Society</i></u>	
President	2002 - 2003
Executive Council (Founding Member)	1993 - Current
Secretary/Treasurer	2017 - Current
Program Committee (Co-Chair)	1994 - 2017

Co-Chair, International Pituitary Congress <i>National</i>	1989 -2019
Acromegaly Centennial Symposium, Co-Chair	1986
Recent Advances in Somatostatin Basic Research Co-Chair	1991
Gordon Research Conference (PRL) Organizing Committee	1996
Vice Chair and Chair, Gordon Research Conference (PRL)	2002, 2004
International Society for NeuroImmuno Modulation, Council	2000 - 2004
USP Council of Experts – Endocrinology Expert Committee	1995 - 2005
Association of Patient Oriented Research (APOR) NIH Advocacy Committee	2005 - 2008
Acromegaly Consensus Conference, Co-Chair	2000 - Current

MEMBERSHIPS IN SCHOLARLY SOCIETIES

Association of American Physicians (elected)
American Society of Clinical Investigation (elected)
American Association of Clinical Endocrinologists
American Federation of Clinical Research
Western Society of Clinical Investigation
Western Association of Physicians
Endocrine Society
Pituitary Society (Founding member)

CONSULTING ACTIVITIES

AMA Drug Evaluations	1993 - 1995
ACP MKSAP Program	1993 - 1995
Pharmacia	1996 - 2001
Chair, GH Advisory Group, Eli Lilly, USA	1995 - 1997
Sensus Corporation	1995 - 2000
Chair, Acromegaly Advisory Group, Novartis	1996 - 2008
Henri Beaufor Institute	1997 - 2000
Current Drugs	1997
Access the Experts Acromegaly	2000 - 2002
Neurocrine	2001
Tercica	2006 - 2008
Global HYPOCCS Advisory Board, Eli Lilly	1995 - 2011
Syntaxin	2009 - 2012
Genentech	2013
Chiasma Pharma	2009 - Current
Ionis	2010 - Current
Ipsen Global	2009 - Current
Rami	2017- 2020
Novartis Global	2010 - 2016
Pfizer	2010 - 2017
Stonebridge	2016 - 2017
Ono Pharma	2016 - 2019
Midatech Pharma	2016 - 2019
Novo-Nordisk	2020

Board Directorships

Board of Directors, Association for the Accreditation of Human Research Protection Programs, Inc. (AAHRPP)	2001 - 2006
--	-------------

Audit Committee (AAHRPP)	2003 - 2006
Accreditation Review Committee (AAHRPP)	2003 - 2006
California Institute of Regenerative Medicine Independent Citizen Oversight Committee (ICOC)	2010 - Current
California Life Sciences Association	2014 - Current
Emulate, Inc.	2014 - Current
Prometheus, Inc.	2018 - 2020
Visby Diagnostics	2019 - Current
BioSciences Los Angeles (BioLA)	2019 - Current

HONORS AND SPECIAL AWARDS

Dale Medal British Society of Endocrinology	2025
Litchfield Lecturer Oxford University, UK	2022
Transatlantic Alliance Award European Soc of Endo and Endo Society	2022
Mortimer Lipsett Award in Endocrinology, NICHD	2021
Distinguished Professor at Cedars-Sinai Medical Center	2020
Litchfield Lecturer Oxford University, UK	2020
American Association of Clinical Endocrinologists, Frontiers in Science Award	2019
Outstanding Scholarly Physician Award of the Endocrine Society	2018
Hospital Physician Leadership Award – LA County Medical Association	2017
Kroc Lectureship, Ohio State University	2017
Visiting Professorship Award in Growth Hormone (Endocrine Society)	2012
Pioneer in Medicine, Cedars-Sinai Medical Center	2011
Endocrine Regulation Prize, Fondation IPSEN	2010
Master of the American College of Physicians	2010
Transatlantic Medal (British Society for Endocrinology)	2010
Pituitary Society Lifetime Achievement Award	2009
Fellow, Royal College of Physicians (Hon)	2007
Endocrine Society Clinical Investigator Award	2004
Honorary Professor, Fudan University, Shanghai	2004
Pituitary Society Award, Contributions to Understanding Pituitary Disease	1997
Honorary Member, German Endocrine Society	1996
Best Doctors in America	1994 - Current
McGill University, Neuro-Endocrinology Award	1995
Royal Society of Medicine, Clinical Endocrinology Trust Medal	1994
Fellow of American College of Physicians	1981
NIAMDD Clinical Investigator Award, NIH	1981

POST-DOCTORAL TRAINEES

Shunichi Yamashita, M.D.	1984-1987	Martha Cruz-Soto, Ph.D.	2003-2006
James Fagin, M.D.	1987-1991	Tami Rubinek, Ph.D.	2003-2006
John Ong, M.D.	1986-1987	Ines Donangelo, MD Ph.D.	2004-2007
Shigeki Morita, M.D.	1987-1989	George Vlotides MD.PhD.	2004-2008
Sarah Pixley, Ph.D.	1987-1989	Yunguang Tong, Ph.D.	2005-2009
Hironori Namba, M.D.	1989-1991	Cuiqi Zhou, Ph.D.	2005-2009
Sawsan Barakat, M.D.	1989-1991	Anna Gruszka, M.D., Ph.D.	2005-2007
Diane Prager, M.D.	1990-1993	Yen Hao Chen, Ph.D.	2006-2008
Vivien Herman, M.D.	1987-1990	Hubina Erika, Ph.D.	2007-2008
Keiichi Matsuo, M.D.	1990-1992	Alexey Resnenko, Ph.D.	2007-2008

Hiro Yamasaki, M.D.	1990-1992	Odelia Cooper, MD	2007-2009
Rivka Gonsky, Ph.D.	1990-1993	Weijiang Zhao, Ph.D.	2000
Mathew Weber, M.D.	1992-1994	Magdalena Uhart, M.D.	2008-2014
Shereen Ezzat, M.D.	1992-1994	Hide Fukuoka M.D., Ph.D.	2008-2011
Hiro Yamamoto, M.D.	1993-1995	Yoel Toledano, M.D.	2008-2010
Jonathan Webster, M.D., Ph.D.	1994-1996	Maya Tobita Kano, M.D.	2010-2012
Yona Greenman, M.D.	1994-1996	Alan Parsa, M.D.	2010-2012
Lin Pei, M.D., Ph.D.	1994-1996	Takako Araki, M.D.	2011-2016
Hirofumi Takino, M.D.	1994-1996	Yuji Tani, MD, Ph.D.	2012-2013
Stephen Petersen, M.D.	1995-1996	Dan Cuevas-Ramos, M.D.	2012-2014
Ilan Shimon, M.D.	1995-1997	M. Victoria Recouvreaux, Ph.D.	2013-2015
Zhiyong Wang, Ph.D.	1996-2002	Xiaohai Liu, M.D	2013-2014
Sadanori Akita, M.D.	1995-1997	Artak Labadzhyan, M.D.	2013-2015
David Ray, M.D., Ph.D.	1995-1997	Masaaki Yamamoto, M.D.	2014-2018
Xun Zhang, Ph.D.	1996-1998	Hiraku Kameda, M.D.	2015-2018
Marlys Drange, M.D., Ph.D.	1996-1999	Asha Pathak, M.D.	2018-2020
Alberto Valentini, M.D.	1996-1998	Naomi Even Zohar, M.D., Ph.D.	2019-2023
Hiroki Yano, M.D.	1996-1998	Derya Metin-Armagan, Ph.D.	2018-Current
Masahiro Nakashima, M.D.	1996-1998	Kohei Yamamoto, M.D., Ph.D.	2021-Current
Anthony Heaney, M.D., Ph.D.	1997-2000	Kyungwon Kim, Ph.D.	2021-Current
Chris Auernhammer, M.D.	1997-1999		
Marcelo Perrone, Ph.D.	1998-1999		
Pinar Kadioglu, M.D.	1998-1999		
Maria Zatelli, M.D.	1998-2000		
Vera Chesnokova, M.D.	1998-2000		
Hiroki Ishikawa, M.D.	1999-2001		
Chris McCabe, Ph.D.	1999		
Ruchi Mathur, MD	1999-2000		
Run Yu, M.D., Ph.D.	1999-2004		
Hiralal Maheshwari, M.D.	1999-2003		
Ana Valeria Barros De Castro, M.D., Ph.D.	2000-2002		
Rula Abbud, MD, Ph.D.	2000-2005		
Anat Ben-Shlomo, M.D.	2000-2005		
Ichiro Takumi, M.D.	2000-2001		
Kozo Akino, M.D.	2000-2001		
Anastasia Kariagina, Ph.D.	2000-2003		
Helen Turner, M.D.	2001		
Robert Murray, M.D.	2001-2003		
Ningai Liu, M.D., Ph.D.	2001-2003		
Irina Miklovsky, PhD	2001-2004		
Enrico Moro, Ph.D.	2002-2003		
Merav Fraenkel, M.D.	2002-2004		
Sergio Licalzi, Ph.D.	2002-2004		

PRE-DOCTORAL TRAINEES

Beatrice Stefana, M.Pharm	1995-1997
Elena Faccenda, M.S.	1995-1997

Anita Huttner, M.S.	1996
Corinne Bousquet, Ph.D. (Doctoral)	1996-2000
Gregg Horwitz, Ph.D. (Masters)	1998-2001
Kolja Wawrowsky, Ph.D. (Doctoral)	2004-2007
Tamar Eigler, Ph.D. (Doctoral)	2010-2013

INDIVIDUAL TRAINING FUNDING & AWARDS

<i>James Fagin, (P. I.)</i>	1985 - 1987
NRSA Individual Training Award (NIADDK)	
American Thyroid Association Travel Award	1986
NIH, FIRST Award	1989 – 1994
<i>Sarah Pixley, NIH Summer Trainee Award</i>	1986
<i>Shunichi Yamashita, (P. I.)</i>	1986 – 1988
ADA Research Fellowship Award	
Research Trainee Award, Crosstown Endocrine Club	1985
International Thyroid Association, Travel Award	
WSCI Outstanding Trainee Award	1986 – 1987
Dean of Graduate School of Biomedical Sciences	
Nagasaki University School of Medicine	
<i>John Ong, WSCI Outstanding Trainee Award</i>	1988
<i>Diane Prager, (P. I.)</i>	1988 - 1990
ADA Research Fellowship Award	
WSCI Outstanding Trainee Award	1988
Crosstown Endocrine Club	
AFCR Trainee Award (National)	1989
Solomon Scholar Trainee Research Award	1990
NIDDK Clinical Investigator Award	1991 – 1996
<i>Shereen Ezzat, American Thyroid Association Travel Award</i>	1989
<i>Hiro Yamasaki, WSCI Outstanding Endocrinology Trainee</i>	1989
<i>Vivien Herman-Bonert, NIH Clinical Investigator Award</i>	1991 – 1996
<i>Lin Pei, AFCR Trainee Award (National)</i>	1995
Endocrine Society Travel Award	1996
NIH Clinical Investigator Award	1995 – 2001
<i>Ted Friedman, NIDA New Investigator Award</i>	1995 – 2000
Culpeper Award	1996 – 1998
<i>Masahiro Nakashima</i>	1996 – 1998
Professor and Head of Dept of Tumor and Diagnostic Pathology	
Nagasaki University	
<i>Ilan Shimon, Merck Senior Fellowship Award, Endocrine Society</i>	1997
<i>David Ray, Endocrine Fellows Foundation Award</i>	1997
<i>Chris Auernhammer, Merck Senior Fellowship Award,</i>	1998
Endocrine Society	
<i>Marlys Drange, American College of Physicians,</i>	1997
Regional Scientific Trainee Award;	1998
Endocrine Fellows Foundation Award	
<i>Tony Heaney, Endocrine Fellows Foundation Award</i>	1998
Fullbright Scholarship Award	1999
Merck Senior Fellowship Award, Endocrine Society	1999
Chancellor’s Award, UCLA Postdoctoral Program	2000
International Cardura Competitive Awards, Pfizer	2001

<i>Gregory A. Horwitz</i> , Introduction to Molecular & Cellular Research, Travel Grant Award	1999
Endocrine Society Travel Grant Award	2000
Novartis Junior Investigator Award	2000
<i>Run Yu</i> , Endocrine Society Trainee Award	2000
Lilly Pituitary Scholars Fellowship, Endocrine Society	2001
NIH Clin Investigator Award (K08)	2005-2010
<i>Ning-Ai Liu</i> , 2 nd Annual Pfizer Scholars in Endocrinology Grant Program	2003
Clinical Investigator Award (K08 NIH)	2003-2008
DERC Pilot and Feasibility Grant (UCSD/UCLA)	2010-2011
<i>Cuiqi Zhou</i> , Travel Grant Award, Endocrine Society	2008
<i>Odelia Cooper</i> , NIH (K23) Mentored Patient Oriented Research Award	2009-2014
<i>Hidenori Fukuoka</i> , Travel Grant Award, Endocrine Society	2010
<i>Yunguang Tong</i> , NIH K99 Award	2010-2015
<i>Hidenori Fukuoka</i> , Presidential Competitive and Travel Grant Award, Endocrine Society	2010
Young Investigator Award (YIA), Japan Endocrine Society	2011
<i>Cuiqi Zhou</i> , ASPIRE Young Investigator Award (Pfizer)	2014
<i>Masaaki Yamamoto</i> , Outstanding Abstract Award (Endo Society)	2017
<i>Asha Pathak</i> , Pfizer ASPIRE Award	2019

CURRENT FUNDING:

Ongoing Research Support:

NIH/NIDDK R01DK113998	(Melmed PI)	04/01/2018- 03/31/2028
Mechanisms Underlying Colon Neoplasia in Acromegaly This project is studying the effects of epithelial non-pituitary GH secretion on DNA damage and senescence, particularly in aging.		
FDA R01FD006106	(Melmed PI)	09/01/2018 – 8/31/2024
Phase 2 Multicenter Study of Seliciclib for Cushing Disease The goal of this project is to evaluate the safety and efficacy of seliciclib in a phase 2 multicenter trial of patients with Cushing disease.		
NIH/NIDDK T32DK007770	(Melmed PI)	08/01/1999 – 06/30/2024
Institutional Training Program in Endocrinology, Diabetes, and Metabolism The goal of this project is to fund post-doctoral fellows in Endocrinology at Cedars-Sinai Medical Center.		
Recordati Rare Diseases	(Melmed PI)	02/01/2022 – 12/01/2027
National US Pituitary Adenoma Surveillance Registry This is an investigator-initiated prospective registry of pituitary adenoma patients treated at multidisciplinary pituitary centers in the United States.		
Doris Factor Endowed Molecular Endocrinology Laboratory	(Melmed PI)	08/01/1989-Current
Molecular Mechanisms of Hormone Action in Target Cells and Transgenic Animals This permanently endowed laboratory supports research support for molecular endocrinology.		

Cedars-Sinai Research Institute (Melmed PI) **09/01/2002-12/31/2024**

Pituitary Tumor Surveillance: Pathogenic Correlation

This data/specimen registry aims to observe aspects of pituitary tumor recurrence and markers of persistent disease. The second goal is to evaluate long-term consequences of hormone replacement therapy for pituitary hormone insufficiency, as this is an independent risk factor for premature death.

INVITED LECTURES AND PRESENTATIONS (SELECTED):

1986	38th Postgraduate Assembly of Endocrine Society, Los Angeles	Invited speaker
1987	39th Postgraduate Assembly of Endocrine Society, San Francisco	Invited speaker
1988	UCSF, Peptidomimetic Therapy: A novel approach to endocrine and GI diseases	Invited speaker
1989	European Neuro-Endocrine Association, London Baylor University, Peptidomimetic Therapy Symposium 2 nd International Pituitary Congress, Palm Desert, CA	Plenary Invited speaker Chair
1990	Pituitary Pathology Workshop, 4th Annual Meeting, Lyon, France Endocrine Society, 42nd Postgraduate Assembly, Honolulu, Hawaii University of Oregon Health Sciences, Nobel Wiley Jones Lectureship University of Washington, Seattle Leonard Visiting Professor of Medicine	Plenary Plenary Award Lecture Invited speaker
1991	Endocrine Society: Introduction to Endocrine Investigation Spanish Endocrine Society: Annual Mtg., Santiago Somatostatin State-of-the-Art: Basic and Clinical Aspects, Monte Carlo 5th European Pituitary Workshop, Venice	Invited speaker Plenary Invited speaker Plenary
1992	Endocrine Society Symposium: Management of pituitary tumors, San Antonio NY Academy of Sciences: Role of IGF-I in the CNS, Arlington Intl Symposium on GH: Tarpon Springs, Florida	Invited speaker Invited speaker Invited speaker
1993	Somatostatin receptor imaging, Amsterdam, Netherlands Endocrine Society of Australia, Annual meeting, Ayers Rock, (Plenary) Garvin Institute of Medical Research, Sydney, Australia Third International Pituitary Congress, Los Angeles Sixth Prolactin Congress, Paris Israel Endocrine Society, Annual Mtg, Jerusalem 45th Postgraduate Assembly, Endocrine Society, San Francisco, Management of pituitary tumors Serono Symposia, San Diego, GH and IGF-I: Basic and Clinical Advances	Invited speaker Plenary Invited speaker Chair Invited speaker Plenary Invited speaker Invited speaker
1994	Colorado Diabetes/Endocrine Institute, Aspen, Colorado Gordon Research Conference (Prolactin), Oxnard Harvard Medical School, Boston, Clinical Endocrinology Update Japan Endo Soc, Satellite: Recent advances in Pituitary Research Japan Endocrine Society Royal Society of Medicine, CERSM Visiting Professor at UK Med Schools British Endocrine Society	Invited speaker Invited speaker Invited speaker Chair Plenary Award speaker Plenary

	British Growth Factor Group	Invited speaker
	European Endocrine Society, Amsterdam	Invited speaker
	McGill University Sandoz Neurendocrine Visiting Professor, Montreal	Award speaker
	Endocrine Society Meeting, Anaheim, Management of Acromegaly	Invited speaker
	Endocrine Society Annual Meeting Symposium on IGF-I	Invited speaker
	Endocrine Nurses Society 4th Annual Symposium, California	Invited speaker
1995	UCSF: State-of-the-Art Conference on Pituitary Tumors	Invited speaker
	Oregon Health Sciences University - Endocrine Club	Invited speaker
	Philadelphia Endocrine Society	Invited speaker
	Endocrine Postgraduate Course, Harvard Medical School	Invited speaker
	Recent Progress in Hormone Research 51st Conference, Stevenson, Washington	Invited speaker
	5th International Insulin and IGF Symposium, Gainesville, Florida	Invited speaker
	International Growth Symposium, Santiago de Compostela, Spain	Invited speaker
	Somatostatin Analogs: Basic and Clinical Perspectives, Sorrento, Italy	Invited speaker
1996	Clinical Endocrinology Update; Endocrine Society, San Diego	Invited speaker
	4th International Pituitary Congress, San Diego, CA	Chair
	6th European Workshop on Pituitary Adenomas, Berlin, Germany	Plenary
	21st International Symposium: GH & GH factors, Venice, Italy	Invited speaker
	2nd International Skull Base Congress, San Diego	Invited speaker
	University of Miami School of Medicine, Visiting Professor, Florida	Invited speaker
	South Florida Endocrine Society	Invited speaker
	Neuro-immuno-endocrine Networks, NAITO Foundation Nogoya, Japan	Plenary
	International Society for Neuro-immunomodulation, Bethesda, MD	Invited speaker
	Biological & Clinical Relevance of the SMS Receptor, Yale, New Haven,	Invited speaker
	Mt. Sinai School of Medicine, NY - Visiting Professor	Invited speaker
1997	Neuro-endocrine-Immunology, Gordon Conference - Ventura, CA	Invited speaker
	Diagnosis and Treatment of Pituitary Insufficiency, Indianapolis, IN	Invited speaker
	Sandostatin LAR Meeting, Innsbruck, Austria	Plenary
	Endocrine Society 79 th Ann Mtg, Meet the Professor, Minneapolis	Invited speaker
	European Neuroendocrine Association, Marseille, France	Invited speaker
	Symposium on New aspects of somatostatin analogues, Oslo, Norway	Invited speaker
	Intl Symposium on SMS analogs: Basic update and clinical perspectives, Venice, Italy	Invited speaker
	UCSD -Visiting Lecturer, Endocrinology	Invited speaker
	Scandinavian Symposium on Pituitary Adenomas, Oslo, Norway	Plenary
1998	Intl Symposium GH: New Clinical Applications, Marbella, Spain	Invited speaker
	5 th International Pituitary Congress, Naples, Florida	Invited speaker
	Oregon Health Sciences University, Visiting Professor, Endocrinology	Invited speaker
	HYPOCCS Symp, Pathogenesis of pituitary tumors, Seville, Spain	Invited speaker
	Beufour Ipsen, "Overview of Pituitary tumor management" Seville, Spain	Invited speaker
	European Federation of Endocrine Society, Seville, Spain	Plenary
	Endocrine Society, Growth hormone deficiency in Adults, New Orleans	Invited speaker
	Endocrine Society Symposium: "Acromegaly: Pharmacotherapy", New Orleans	Invited speaker
	5 th International Pituitary Congress, "Pituitary Oncogenes", Naples, Florida	Chair

	University of Illinois, Chicago, Visiting Professor	Invited speaker
	2 nd Parnas Conference, “Regulation of pituitary function” Gdansk, Poland	Plenary
	Southern Nevada Endocrine Society, “Indications for GH therapy”	Invited speaker
	Society for History of Medicine “GH from Goliath to receptors”, Los Angeles,	Invited speaker
	Prince Henry’s Trust, “Pituitary Growth Factors”, Melbourne, Australia	Award speaker
1999	Criteria for cure of acromegaly: in search of a consensus, Cortina, Italy	Co-Chair
	Otreotide: the next Decennium, Sintra, Portugal	Invited speaker
	New pituitary oncogenes, British Endocrine Society, Bournemouth, UK	Invited speaker
	Dopamine resistant prolactinomas ENEA Mtg. Copenhagen, Denmark	Invited speaker
	John Hopkins School of Medicine, Endocrinology	Invited speaker
	Annual Meeting Endocrine Society Symposium, Pituitary Oncogenes	Invited speaker
	Controversies in Acromegaly, San Diego	Invited speaker
	GH/IGF-I Workshop, Pasadena	Chair
	Simposio Internacional Sobre Hipofisaria, Buenos Aires, Argentina	Invited speaker
	International Symposium of Neuroendocrinology, Curitiba, Brazil	Invited speaker
	Clinical Endocrinology Update '99, (Endocrine Society), Pituitary Section	Chair
2000	Acromegaly Workshop (Co-Chair), Monte Carlo, France	Invited speaker
	Endocrine Society Symposium – “Does acromegaly cause cancer?”, Toronto	Invited speaker
	4 th Annual HypoCCS Symposium and Investigators Meeting Toronto	Chair
	FASEB Plenary Lecture, “Cytokines in the pituitary”, San Diego	Plenary
	American Assoc of Neurological Surgeons, “Recurrent Pituitary Tumors”	Plenary
	German Endocrine Society “Acromegaly: has time come for primary medical treatment?” and “Pathogenesis of pituitary adenomas”, Munich	Plenary
	7 th European Pituitary Workshop “New pituitary oncogenes”, Oxford, UK	Plenary
	11 th Intl Congress of Endocrinology, “Pathogenesis of pituitary tumors”	Invited speaker
	Sydney, Australia	
	Oxford Union Debate: Therapy of acromegaly	Plenary
	Visiting Professor, Endocrinology, UCSF	Invited speaker
	Visiting Professor, Northwestern University School of Medicine, Chicago	Invited speaker
2001	43 rd Spanish Congress of Endocrinology, Santiago de Compostela, Spain	Plenary
	83 rd Annual Mtg Endocrine Society, Denver, Colorado	Invited speaker
	“Integration of Endocrine Indications for Somatostatin Analogs”	Invited speaker
	GH Symposium, “Excess GH and cancer in adults” Tampa, Florida	Invited speaker
2002	Prolactin Gordon Research Conference, Ventura, California	Vice-Chair
	American Federation of Medical Research, “Cytokine receptor-mediated regulation of pituitary function” Carmel, CA	Plenary
	HYPOCCS Symposium, “Mechanisms of pituitary disease” Miami, Florida	Invited speaker
	Endo Symposium, “Novel therapies for pituitary tumors”, San Francisco	Invited speaker
	Acromegaly 2002 and Beyond, “Genetic Syndromes”, San Francisco	Invited speaker
	Brigham and Womens Hospitals, Boston	Invited speaker
	3 rd Acromegaly Consensus Conference: Diagnosis & Treatment of acromegaly complications, “Medical treatment options” Versailles, France	Chair
	Nicholas T. Zervas Award Lectureship, Harvard Medical School,	Award Lecture
	Massachusetts General Hospital, “Cell cycle lessons from pituitary adenomas”	

	European Neuroendocrine Association, “Pituitary oncogenesis” Munich, Germany	Plenary
	Endocrine Interventions in aging: Growth Hormone, Univ of South Florida, “GH and cancer”	Invited speaker
	Endocrine Grand Rounds, Univ of California San Diego, “Acromegaly”	Invited speaker
2003	8 th Intl. Congress, “Molecular Pathogenesis of Pituitary Tumors”, NY	Invited speaker
	Global Endocrine Care Summit, “Mortality of Acromegaly”, Barcelona	Invited speaker
	Endocrine Board Review Course, University of California San Diego	Invited speaker
	4 th Consensus Workshop on Acromegaly “Medical Treatment”, Spain	Chair
	Pituitary Young Investigators Meeting, Nevada	Chair
2004	Annual Meeting Japan Endocrine Society, International satellite symposium, Kyoto “Zebrafish pituitary development and regulation”,	Plenary
	Honorary Professor and Chair, Acromegaly consensus guidelines for Asia Pacific and Latin America, Fudan University, Shanghai “Goals of clinical management for acromegaly”	Award Lecture
	Prolactin Gordon Conference, Oxnard, CA	Chair
	International Congress of Endocrinology, Lisbon, Portugal	Chair
	Satellite Symposium, 12 th ICE “Acromegaly: new development in therapy”	Invited speaker
	Visiting Professor, New York University, New York	Invited speaker
	Endocrine Society Clinical Investigator Award Lecture, New Orleans, Louisiana	Award Lecture
	Endocrine Fellows Foundation “Basic aspects of pituitary function”	Invited speaker
	European Neuroendocrine Association, Naples, Italy	Invited speaker
	Societa Italiana Di Endocrinologia, Sie Lombardia Lecture “Oncogenesis of pituitary tumors”	Plenary
	Argentine Endocrine Society, Buenos Aires – “Advances in hypophyseal tumorigenesis” and “Controversies in the treatment of acromegaly”	Plenary
	Endocrinology and Metabolism Brazilian Congress, “Acromegaly-clinical treatment”	Plenary
2005	HYPOCCS Molecular Pathogenesis and Therapy of Pituitary Disease Madrid, Spain	Invited speaker
	University of California San Diego - Endocrine Grand Rnds	Invited speaker
	Robert L. Ney Visiting Professor, Johns Hopkins University, MD	Award Lecture
	Colloques Medecine et Recherche, “Receptor function and new drug targets”, Paris, France	Invited speaker
	Pituitary Today: Molecular, physiological and clinical aspects”, Argentina-Brazil, Iguazu	Invited speaker
	International Workshop “Somatostatin update”, Turin, Italy	Invited speaker
	California Chapter of AACE, 5 th Annual Mtg “Update on Management of Acromegaly	Invited speaker
2006	V Consensus Meeting “Guidelines for treatment of GH excess and GH deficiency” Santa Monica	Chair
	Yogesh Patel Memorial Lecture “Pituitary Tumor Pathogenesis” McGill University, Sandoz Award	Award Lecture
	Visiting Professor, Dean’s Lecture: “How to succeed in Academic Medicine” University of South Florida, Tampa	Award Lecture

	National Symposium on Pituitary Disorders: “Evaluation of pituitary mass treatment of acromegaly”, University of South Florida, Tampa.	Invited speaker
	“Pituitary trophic status”, Ipsen Fndn Hormonal Control of Cell Cycle Paris	Invited speaker
	Growth and Signaling: Pathogenesis of pituitary tumors, Inserm, Paris	Invited speaker
2007	“Update on Acromegaly Management” UCSF, San Francisco, CA	Invited speaker
	UCSD Endocrine Grand Rounds, “Mechanisms for pituitary tumorigenesis”	Invited speaker
	International Workshop on Treatment of Cushing’s Syndrome, Budapest	Invited speaker
	The Endocrine Society 89 th Meeting, “The Year in Pituitary” Toronto	Invited speaker
2008	Prolactin and GH Gordon Conference, Ventura, Pituitary Tumor Pathogenesis	Invited speaker
	Pituitary Expert Symposium, Pituitary Senescence, Florence, Ital	Invited speaker
	Endocrine Society, “Pituitary disorders and tumors, San Francisco, CA	Invited speaker
	Grand Rounds “Acromegaly” University of Tucson, Tucson, AZ	Invited speaker
	Pituitary Today II: Molecular, Physiological and Clinical Aspects. Brazil	Invited speaker
2009	Western Soc for Clin Investigation. “Pituitary Tumor Pathogenesis”	Plenary
	International Pituitary Congress, Washington, DC	Co-Chair
	Bridges in Life Sciences US-CEE Regional networking Mtg IV, “Molecular Mechanisms for Pituitary Tumorigenesis:” Debrecen, Hungary	Plenary
	Acromegaly Consensus Criteria for Cure: Cortina revisited after 10 years”, Paris	Chair
2010	British Society of Endocrinology: Transatlantic Lecture, “Pituitary Tumor Pathogenesis”, Manchester, UK	Award Lecture
	Pfizer Visiting Professor, Mount Sinai Medical Center, New York	Invited speaker
	Endocrine Society Trainee Day, Plenary “Discovery in Pituitary Medicine”, San Diego	Invited speaker
	Endocrine Society Symposium, “Targeted therapy for pituitary tumors”, San Diego	Invited speaker
	Congress of European Neuroendocrine Association - Fondation Ipsen	Award Lecture
	Endocrine Regulation Prize Lecture Liege, Belgium	
2011	American Assoc of Clinical Endocrinology “Medical therapy for acromegaly”, San Diego	Invited speaker
	European Congress of Endocrinology “Acromegaly treatment resistance”, Rotterdam, NL	Plenary
	Pan-European Meeting Management of Acromegaly, Athens, Greece	Invited speaker
	Knowledge Forum, “The science of acromegaly: molecular and genetic insights”, Germany	Invited speaker
2012	“Clinical and Economic Impact of Acromegaly”, Regional Cooperation for Health, Science and Technology Consortium, Budapest, Hungary	Invited speaker
	Management for acromegaly and cushing’s disease”, City of Hope, Duarte	Invited speaker
	Emory University, Medicine Grand Rounds, “Focus on Pituitary Tumors: Progress in Medical Management for Acromegaly and Cushing Disease”	Invited speaker
	Emory University, “New targets for pituitary tumor therapy”	
	Amer Assoc of Clinical Endo “Management for Acromegaly and Cushing Disease”, Atlanta, GA	Invited speaker

	15 th International Congress of Endocrinology/14 th European Congress of Endocrinology “Genes involved in pituitary tumorigenesis” & “Economic value of disease control”, Florence, Italy	Invited speaker
	Italian Endo Society “Pathogenesis of Pituitary Adenomas”, Brescia, Italy	Plenary
	Updates in Cushing’s Disease: Pituitary Society Workshop Toronto, Canada	Chair
2013	9th Acromegaly Consensus: “Medical Treatment of Acromegaly”, Amsterdam, NL	Co-Chair
	Endocrine Society Visiting Professor in GH Regulation and Disorders, University of Colorado	Invited speaker
	13 th International Pituitary Congress, San Francisco, CA	Co-Chair
	Latin American Knowledge Network “New insights into pituitary tumor therapies”	Invited speaker
	15 th European Congress of Endocrinology, Copenhagen, Denmark	Symposium Chair
	Aspiring to Excellence: Pituitary Expert Forum, Stockholm, Sweden	Invited speaker
	CBS 60 minutes Interview “Deer Antler” with Keith Sharman	Invited broadcast
	Memorial Sloan-Kettering Center, NY “Pituitary Tumor Therapeutic Targets”	Invited speaker
	Puerto Rican Society of Endocrinology and Diabetes	Plenary
2014	Int’l. Symposium of Neuroendocrinology, “Acromegaly: management”, Campinas, Brazil	Plenary
	AACE Acromegaly: Assessing the Disorder and Therapy Las Vegas, NV	Chair
	Endo CMES Acromegaly: Diagnosis and Management Options,” Chicago	Invited speaker
	European Neuroendocrine Association: “Why are pituitary tumors benign?” Sofia, Bulgaria	Plenary
2015	John Wayne Cancer Institute Pituitary Centers of Excellence “What Do We Expect From Our Neurosurgical Colleagues”, Santa Monica, CA	Invited speaker
	Medicine Grand Rounds, UC Irvine Medical Center	Invited speaker
	14 th International Pituitary Congress, San Diego, CA	Co-Chair
	10 th Acromegaly Consensus Conference, Madrid, Spain	Co-Chair
	Endocrine Society Clinical Endocrinology Update, “Update in Management of Pituitary Adenomas – Year in Clinical Pituitary”	Invited speaker
	Pituitary Expert Forum, “Molecular targets for pituitary tumors”, Spain	Invited speaker
	UCSF, Pituitary Disorders: Advances in Diagnosis and Management “Pituitary signaling leading to novel therapies”; “Non-surgical approaches for pituitary masses”; “Acromegaly management update”, San Francisco	Invited speaker
	Stem Cell on the Mesa, Alliance for Regenerative Medicine, Advanced Therapies, La Jolla, CA	Invited speaker
2016	Global Pituitary Expert Round Table, Zurich, Switzerland, February	Invited speaker
	AACE Annual Meeting “Does GH keep you younger?” Orlando, FL	Invited speaker
	Advances in Neurosciences and Pituitary Diseases, Las Vegas, NV	Invited speaker
	Pituitary Update, Loma Linda University, CA	Invited speaker
2017	15 th International Pituitary Congress, Orlando, FL,	Co-Chair
	11 th Acromegaly Consensus Conference, Nice, France	Co-Chair
	European Congress of Endocrinology: “Does GH Enable Neoplastic Growth?” Lisbon,	Invited speaker

	Endocrine Society CEU Course, Chicago, IL	Invited speaker
	Oppenheimer Lecturer, Citywide Endocrine Conference, Univ of Minnesota	Invited speaker
2018	N. American Skull Base Society “Acromegaly: Updates in management”, San Diego, CA	Invited speaker
	International Society of Pituitary Surgeons, “Pituitary Centers of Excellence”, San Diego, CA	Invited speaker
	Kroc Visiting Professor at OHSU “Molecular Targets for Novel Pituitary Tumor Therapies” and Medicine Grand Rounds: “Does GH enable neoplastic growth?”	Invited speaker
	12 th Acromegaly Consensus Conf on Acromegaly Complications, Prague	Co-Chair
	70 th Clinical Endocrinology Update, “Treatment of Acromegaly” and “Imaging-based Differential Diagnosis and Management of Pituitary Masses” Miami, FL & Los Angeles, CA	Invited speaker
	Israeli Pituitary Conference: Update on Pituitary Diseases: “Pituitary Hormones in Clinical Medicine: A two-way story” Herzlyia, Israel	Plenary
	International Congress of Endocrinology (ICE), Program, Cape Town, South Africa	Co-Chair
2019	16 th International Pituitary Congress Program, New Orleans, LO	Co-Chair
	Intl. Pituitary Congress “Adult GH deficiency: treatment outcomes”	Invited speaker
	Meet the Professor “Optimizing Outcomes in Acromegaly” Endocrine Society, New Orleans	Invited speaker
	AACE Plenary Lecture, “Zebrafish to Humans: Translating Discoveries for Treatment of Cushing Disease”, Los Angeles, CA,	Plenary
	Pituitary Symposium: “Acromegaly Management”, Memorial Sloan Kettering Cancer, NY	Invited speaker
	Endocrine Society CEU, “Non-functioning Pituitary Adenomas” Miami, FL and Seattle WA	Invited speaker
	13 th Acromegaly Consensus Conference, Fort Lauderdale, FL	Co-Chair
	University of Pennsylvania Diabetes Research Center Pituitary Tumor Molecular Pathogenesis” and “Drug Discovery for Novel Cushing Disease Treatments”	Invited speaker
2020	Endocrine Society CME , “Improving Outcomes in Acromegaly: (Online)	Invited speaker
	Pituitary Society Master Course, “Adult GH deficiency”, (Online)	Invited speaker
	Vindico CME, “Acromegaly treatment paradigms”, (Online)	Invited speaker
	European Congress of Endocrinology (eECE) Acromegaly CME	Invited speaker
	Endocrine Society Webinar, “Oral octreotide: a new option in acromegaly”	Invited speaker
	Endocrine Society Clin Endocrinology Update: Acromegaly management	Invited speaker
	Endocrine Society Clin Endocrinology Update: Hyperprolactinemia	
	Barrow Institute AZ CME: Management of Pituitary masses	Invited speaker
	Barrow Institute AZ CME: Acromegaly Update	
2021	FDA Patient-focused Drug Development Meeting, Scientific Overview: Acromegaly, Washington	Plenary
	Society of Endocrinology/Metabolism and Diabetes of South Africa	Plenary
	Plenaries: “Acromegaly treatment Update/Approach to managing the pituitary mass” and “Cushings Disease from Zebrafish to patients”	

	11 th Emirates Diabetes and Endocrine Congress “Is GH implicated in cancer?”, “Clinical approach to managing the pituitary mass?”, “Acromegaly treatment updates”, Saudi Arabia	Plenary
	Philadelphia Endocrine Society, “Update in Acromegaly”	Invited speaker
	23 rd European Congress of Endocrinology “Evolving acromegaly treatment landscape: Latest updates and comorbidities management”	Invited speaker
	FASEB SRC: GH/PRL in Health and Disease, “Does GH cause cancer?”	Plenary
	GH Research Society “Does GH enable tumorigenesis?”	Plenary
	University of Michigan in Medicine and Endocrinology, “Role of GH signalling in epithelial proliferation	
	NIDDK Mortimer Lipsett Memorial Award, “GH signalling in epithelial proliferation”	Award lecture
	Acromegaly Webtalk: Acromegaly	Invited speaker
	Medscape Program in Acromegaly, “The changing landscape in acromegaly- dissecting guideline updates for improved patient care”	Invited speaker
	eECE Hub “The treatment of landscape: Optimizing care for acromegaly”	Invited speaker
	Endocrine Society of India (ESI), International Pituitary Conclave “Personalized therapy in acromegaly”, India	Invited speaker
	Congresso Paulista de Endocrinologia e Metabologia (COPEM 2021), Brazil	Invited speaker
	Endocrine Society, “Management of Aggressive Pituitary Tumors”, Brazil	
	“Somatuline in the management of Acromegaly”, Dorguerie de l’Union Experts Meeting Beirut, Lebanon	Invited speaker
	AACE Chapters Middle East Conference, “Non-functioning pituitary adenomas”, Dubai	Invited speaker
	Annual USC Pituitary Symposium “Pathogenesis of Pituitary Adenomas”	Invited speaker
	UCSF Grand Rounds “Does GH cause cancer?” and Management of Pituitary Mass?”	
2022	European Society of Endocrinology Transatlantic Alliance	Award lecture
	Transatlantic Alliance joint award of ESE and Endocrine Society “Growth hormone: an adult endocrine misnomer”	Award lecture
	Israel Endocrine Society “Pituitary Neoplasms: Molecular pathogenesis”	Invited lecture
	12 th Emirates Diabetes and Endocrine Virtual Congress (EDEC), “Evaluation of the Pituitary Mass”	Invited speaker
	Acromegaly: “Navigating SSA therapeutic options for acromegaly treatment”, Saudi Arabia	Invited speaker
	University of Oxford Litchfield Award Lectureship	Award lecture
	o “Aging and cancer: Role of growth hormone:	
	o “Pathogenesis of Pituitary Tumours”	
	o “Update on acromegaly pharmacotherapy for the resistant patient”	
	o ‘Pituitary signalling pathways as therapeutic targets”	
2023	Yogesh Patel Memorial Lecture McGill University	Invited lecture
	6 th Annual Weill Cornell Medicine Pituitary Symposium “Pituitary Adenomas: The Evaluation”	Invited speaker
2024	GH Research Society; Does GH cause Cancer? Stockholm	Plenary
	European Neuroendocrine Assoc. Somatostatin . Seville	Plenary
	European Soc Pediatric Endocr. GH and DNA damage. UK	Plenary
	NYU Endocrinology Symposium	Invited speaker

PATENTS ISSUED

1. **Melmed/Akita/Readhead** – Transgenic mouse for pituitary disorders associated with LIF overexpression and/or GH underexpression, and use for testing therapeutic drugs. *US Patent No. 5,824,838, 1998.*
2. **Melmed/Shimon/Culler** – Method of treating hyperprolactinemia and prolactinomas, *US Patent 5,972,893, 1999.*
3. **Melmed/Pei** – Pituitary tumor transforming genes, and related products. *US Patent 6,455,305, 2002.*
4. **Auernhammer/Melmed** – Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans. *United States Patent No. 6,541,244, 2003*
5. **Melmed/Pei** – Compositions a method for determining the presence of human PTTG peptide in a sample. *US Patent No. 6,750,327, 2004*
6. **Melmed/Pei** – Human PTTG polypeptide and method for producing it. *US Patent. 6,900,032, 2005*
7. **Melmed/Pei** – Rat PTTG polypeptide and method for producing it. *US Patent no. 6,911,320, 2005*
8. **Horwitz/Zhang/Melmed** – PTTG Carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation), *US Patent no. 6,894,031, 2005.*
9. **Melmed/Wang** - PTTG knockout rodent as a model to study mechanisms for various physiological phenomena, including diabetes. *US Patent no. 6,909,030, 2005.*
10. **Prezant/Heaney/Melmed** – Method of regulating biological activity of pituitary tumor transforming gene (PTTG) 1 using PTTG2. *US Patent no. 6,913,926, 2005.*
11. **Auernhammer/Melmed** – Transgenic expression from a SOCS-3 promoter in vertebrate cells. *US Patent no. 6,943,018, 2005.*
12. **Horwitz/Zhang/Melmed** – Antibodies against rat pituitary tumor transforming gene carboxy-terminal (PTTG-C) peptides. *US Patent no. 6,835,380, 2004.*
13. **Heaney/Melmed** – Use of (PPAR)-gamma ligands as a treatment for pituitary tumors and associated conditions, such as Cushing's syndrome. *US Patent no. 6,673,823, 2004.*
14. **Heaney/Melmed** - Transgenic cells transfected with pituitary tumor transforming gene (PTTG) expression vectors and uses therefore. *US Patent 7,097,829, 2006.*
15. **Melmed/Fukuoka** – Use of tyrosine kinase inhibitors for treatment of cushing's disease and hypercortisolism". *US Patent pending application no. 61/300,379, 2010, Intl Patent application no. PCT/US11/23247, 2011.*
16. **Tong/Melmed** – PTTG1 as a biomarker for cancer treatment. *US Patent no. 8,216,782 2012.*
17. **Fukuoka/Cooper/Melmed**- *Use of tyrosine kinase inhibitors for treatment of prolactinoma. US Patent 094716, 2011.*
18. **Melmed/Liu** – *Treatment of pituitary corticotroph tumors using R-roscovitine. US Patent No 061601, 2012.*

Complete List of Published Work in MyBibliography:

<https://www.ncbi.nlm.nih.gov/myncbi/shlomo.melmed.1/bibliography/public/>

BIBLIOGRAPHY

PEER-REVIEWED PUBLICATIONS:

1. Lewin L, **MELMED S**, Bank H: Rapid screening test for detection of elevated myo-inositol levels in human serum. *Clin Chimica Acta* 54:377, 1974. PMID: 4137908
2. **MELMED S**, Bank H, Lewin L: Clinical significance of increased serum myo-inositol levels. *Israel J Med Sci* 10:1518, 1974. PMID: 4140854
3. **MELMED S**, Bank H: Letter: Metoclopramide and facial dyskinesias. *Brit Med J* 1:331, 1975. PMID: 1111802 PMCID: PMC1672508
4. **MELMED S**, Bank H: Meningitis complicated by eighth nerve deafness and arthritis. *Harefuah* 79:22, 1975.

5. **MELMED S**, Lewin L, Bank H: Myo-inositol-metabolic and clinical aspects. Harefuah 79:472, 1975.
6. **MELMED S**, Bank H, Katz D: Streptococcal pancarditis. Chest 69:108, 1976. PMID: 1244263
7. **MELMED S**, Lewin L, Bank H: Serum myo-inositol concentration in impaired renal function. Proc 13th Int Congress Int Med Helsinki p 139, 1976.
8. Bank H, **MELMED S**, Gross S: Azathioprine in the management of subacute thyroiditis. Proc 13th Int Congress Int Med Helsinki p. 85, 1976.
9. **MELMED S**, Lewin L, Bank H: Myo-inositol clearance in renal failure and in patients with normal kidney function. Am J Med Sci 274:55, 1977. PMID: 900156
10. **MELMED S**, Martinovitz U, Bank H: Meningo-myelitis associated with mycoplasma pneumoniae pneumonia. Harefuah 82:353, 1977.
11. Agranat O, **MELMED S**, Altman G, Bank H: Bacterial and fungal meningitis: 22 year survey in a large general hospital. Israel J Med Sci 13:1151, 1977. PMID: 598994
12. Lewin L, **MELMED S**, Passwell J, Brish M, Boichis H, Bank H: Myo-inositol in human neonates: Serum concentrations and renal handling. Pediatric Research 12:3, 1978. PMID: 643373
13. Sharon P, **MELMED S**, Neuman G: Acute pancreatitis in a community with a low alcohol intake. Int Surg 64:64, 1979. PMID: 536146
14. **MELMED S**, Kurtzman G, Reed A, Hershman JM: Non-thyrotropic pituitary cells in culture convert T4 to T3. Life Sci 24:1947, 1979. PMID: 459693
15. **MELMED S**, Harada A, Murata Y, Reed A, Carlson H, Azukizawa M, Martin C, Jorgensen E, Hershman JM: Fetal responses to TRH after thyroid hormone administration to the rhesus monkey: Lack of pituitary suppression. Endocrinology 105:334, 1979. PMID: 110579
16. Morley JE, Barnetsky N, Wingert T, Carlson HE, Hershman JM, **MELMED S**, Levin SR, Weitzman R, Chang RJ, Varner AA: Endocrine effects of naloxone-induced opiate receptor blockade. J Clin Endocrinol Metab 50:251, 1980. PMID: 6243662
17. Morley JE, **MELMED S**, Reed A, Kasson BG, Levin RS, Pekary AE, Hershman M: Effect of vitamin A on the hypothalamic-pituitary-thyroid axis. Am J Physiol 238:E174, 1980. PMID: 6244741
18. **MELMED S**, Harada A, Hershman JM, Krishnamurthy T, Bland W: Neutralizing antibodies in immunized patients with thyroid carcinoma. J Clin Endocrinol Metab 51:358-63, 1980. PMID: 7400301
19. **MELMED S**, Spira O, Gordon A, Gross J, Hershman JM: Suppression of TSH by 3, 5, dimethyl-3'-isopropyl-L-thyronine in euthyroid and hypothyroid rats. Endocrinology 107:1050, 1980. PMID: 7408758
20. **MELMED S**, Carlson HE, Murata Y, Socol M, Hershman JM: Fetal and maternal growth hormone levels in the rhesus monkey: Responses to TRH. Neuroendocrinol Lett 1:89, 1979.
21. **MELMED S**, Carlson HE, Briggs J, Hershman JM: Cell culture alters the hormonal responses of rat pituitary tumors to dynamic stimulations. Endocrinology 107:789, 1980. PMID: 6105070
22. **MELMED S**, Carlson HE, Briggs JE, Hershman JM: Autofeedback of prolactin in cultured pituitary cells. Horm Res 12:340, 1980. PMID: 7419165
23. Sack J, Sazbon L, **MELMED S**, Lunenfeld B, Najenson T: Low serum triiodothyronine and reverse triiodothyronine concentrations in patients with prolonged coma. Israel J Med Sci. 16:402, 1980. PMID: 6772596
24. **MELMED S**, Nelson M, Kaplowitz N, Yamada T, Hershman JM: Glutathione-dependent thyroxine 5'-monodeiodination modulates growth hormone production by cultured non-thyrotropic rat pituitary cells. Endocrinology, 108:970-976, 1981. PMID: 7460854
25. Sharp B, Morley JE, Carlson HE, **MELMED S**, Hershman JM: The role of opiates and endogenous opioid peptides in the regulation of rat TSH secretion. Brain Research 219:335-344, 1981. PMID: 6266605

26. **MELMED S**, Park J, Hershman JM: Triiodothyronine induces a transferable factor which suppresses TSH secretion in cultured mouse thyrotropic tumor cells. Biochem Biophys Res Comm 98:1022-1028, 1981. PMID: 6784729
27. **MELMED S**, Nademanee K, Reed AW, Hendrickson J, Singh BN, Hershman JM: Hyperthyroxinemia with bradycardia and normal thyrotropin secretion after chronic amiodarone administration. J Clin Endocrinol Metab 53:997-1001, 1981. PMID: 7287882
28. Neufeld N, **MELMED S**: 3,5,-dimethyl-3'-isopropyl-L-thyronine therapy in diabetic pregnancy: Stimulation of fetal lung phospholipids. J Clin Invest 68:1605-1609, 1981. PMID: 7033290 PMCID: PMC370967
29. **MELMED S**: Bromocriptine inhibits colony formation by rat pituitary tumor cells in a double-layered agar colonogenic assay. Endocrinology 109:2258-2260, 1981. PMID: 7308152
30. Socol ML, Druzin ML, Murata Y, **MELMED S**, Martin C Jr., Hershman JM: A cyclic variation in thyroid-stimulating hormone in the fetal rhesus monkey. Am J Obstet Gynecol 139:712-714, 1981. PMID: 7211976
31. **MELMED S**, Odenheimer D, Carlson HE, Hershman JM: Establishment of functional human pituitary tumor cell cultures. In Vitro 18:35-42, 1982. PMID: 6820653
32. Sharp B, **MELMED S**, Goldberg R, Carlson HE, Refetoff S, Hershman JM: Radioimmunoassay detection of endorphin from longterm culture of human pituitary tumor cells. Acta Endocrinol 99:174-178, 1982. PMID: 6277127
33. **MELMED S**, Carlson HE, Hershman JM: Histidyl-proline diketopiperazine suppresses prolactin secretion in human pituitary tumor cell cultures. Clin Endocrinol 16:97-100, 1982. PMID: 7074974
34. Lewin LM, Yannai Y, **MELMED S**, Weiss M: Myo-inositol in the reproductive tract of the female rat. Int J Biochem 14:147-150, 1982. PMID: 7200041
35. **MELMED S**, Geola F, Reed AW, Pekary AE, Park J, Hershman JM: A comparison of methods for assessing thyroid function in non-thyroid illness. J Clin Endocrinol Metab 54:300-306, 1982. PMID: 6172442
36. Nademanee K, Singh BN, Hendrickson JA, Reed AW, **MELMED S**, Hershman JM: Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: A potential method for monitoring chronic drug therapy. Circulation 66:202-211, 1982. PMID: 7083508
37. **MELMED S**: GH3 rat pituitary tumor cells are deficient in hypoxanthine-guanine phosphoribosyl transferase activity. Biochem Biophys Res Commun 108:1460-1466, 1982. PMID: 7181902
38. **MELMED S**, Braunstein GD, Hershman JM, Wade MC: Modulation of ectopic secretion of human chorionic gonadotropin by cultured ovarian adenocarcinoma cells. Gynecol Oncol 16:49-55, 1983. PMID: 6309619
39. **MELMED S**, Braunstein GD: Human chorionic gonadotropin stimulates proliferation of Nb 2 rat lymphoma cells. J Clin Endocrinol Metab 56:1068-1070, 1983. PMID: 6187762
40. **MELMED S**: Isolation of human x mouse somatic cell hybrids producing human prolactin: Dominant expression of hormone secretion and regulation. J Clin Endocrinol Metab 56:1145-1151, 1983. PMID: 6404919
41. Cheung CY, **MELMED S**, Braunstein GD: Dopaminergic regulation of prolactin and growth hormone synthesis in rat pituitary tumor cells. Brain Research 270:165-168, 1983. PMID: 6871710
42. Davidson MB, **MELMED S**: Hepatocyte insulin binding and action in rats with sommatomammotrophic tumors. Diabetologia 25:60-65, 1983. PMID: 6350086
43. **MELMED S**: Insulin suppresses growth hormone secretion by rat pituitary cells. J Clin Invest 73:1425-1433, 1984. PMID: 6371058 PMCID: PMC425166
44. Gilbert PL, Siegel RJ, **MELMED S**, Sherman CT, Fishbein MC: Cardiac morphology in rats with growth hormone-producing tumors. J Mol Cell Cardiol 17:805-811, 1985. PMID: 2931534
45. **MELMED S**, Ezrin C, Kovacs K, Goodman R, Frohman LA: Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet cell tumor. New Engl J Med 312:9-17, 1985. PMID: 2981107

46. **MELMED S**, Neilson L, Slanina S: Insulin suppresses rat growth hormone messenger RNA levels in rat pituitary tumor cells. *Diabetes* 34:409-412, 1985. PMID: 3882504
47. **MELMED S**, Slanina SM: Insulin suppresses triiodothyronine-induced growth hormone secretion by GH3 rat pituitary cells. *Endocrinology* 117:532-537, 1985. PMID: 3893986
48. Draznin B, Mehler PS, Leitner JW, Sussman KE, Dahl R, Vatter A, **MELMED S**: Localization of somatostatin receptors in secretion vesicles in anterior pituitary cells and pancreatic islets. *J Recept Res* 5:83-103, 1985. PMID: 2860248
49. **MELMED S**, Fagin J, Leung M: Bromocriptine inhibits incorporation of 3H-thymidine into rat pituitary tumor cells. *Brain Research* 369:83-90, 1986. PMID: 3697756
50. Yamashita S, **MELMED S**: Insulin-like growth factor I action on rat anterior pituitary cells: Suppression of growth hormone secretion and messenger RNA levels. *Endocrinology* 118:176-182, 1986. PMID: 3079701
51. **MELMED S**, Fagin J: Isolation and characterization of rat-mouse somatostatin cell hybrids secreting growth hormone and prolactin. *Exptl Cell Res* 162:475-485, 1986. PMID: 3510881
52. Yamashita S, **MELMED S**: Suppression of triiodothyronine-induced growth hormone messenger RNA by insulin-like growth factor-I in thyroidectomized rat pituitary cells. *Frontiers in Thyroidology* 1:697-700, 1986.
53. Yamashita S, **MELMED S**: Effects of insulin on rat anterior pituitary cells: Inhibition of growth hormone secretion and mRNA levels. *Diabetes* 35:440-447, 1986. PMID: 3082700
54. Yamashita S, Slanina S, Kado H, **MELMED S**: Autoregulation of pituitary growth hormone mRNA levels in rats bearing transplantable mammosomatotropic pituitary tumors. *Endocrinology* 118:915-918, 1986. PMID: 3948780
55. **MELMED S**, Yamashita S: Insulin-like growth Factor-I action on hypothyroid rat pituitary cells: Suppression of triiodothyronine-induced growth hormone secretion and messenger RNA levels. *Endocrinology* 118:1483-1490, 1986. PMID: 3948790
56. Neufeld ND, Braunstein GD, **MELMED S**, Corbo L, Rasor J: Prenatal Therapy in Experimental Diabetic Pregnancy: Association with Fetal Lung Maturity. *J of Perinatology* Vol VI(2) pp, 101-107, 1986.
57. Karpf D, Yamashita S, **MELMED S**, Kudish H, Braunstein GD: In vitro secretion of deoxycorticosterone by a benign Leydig cell tumor of the testis. *J Urol* 136:114, 1986. PMID: 3712595
58. Yamashita S, Weiss M, **MELMED S**: Insulin-like growth-factor I regulates growth hormone secretion and messenger RNA levels in human pituitary tumor cells. *J Clin Endocrinol Metab* 63:730-735, 1986. PMID: 3016022 DOI: 10.1210/jcem-63-3-730
59. Yamashita S, Ong J, Fagin JA, **MELMED S**: Expression of the myc cellular oncogene in human thyroid tissues. *J Clin Endocrinol Metab* 63:1170-1173, 1986. PMID: 3760117
60. Yamashita S, **MELMED S**: Insulin regulation of rat growth hormone gene transcription. *J Clin Invest* 78:1008-1014, 1986. PMID: 3531235 PMCID: PMC423746
61. Ong J, Yamashita S, **MELMED S**: Insulin-like growth factor I induces c-fos messenger RNA in L6 rat skeletal muscle cells. *Endocrinology* 120:353-357, 1987. PMID: 3536454
62. Fagin JA, **MELMED S**: Relative increase in insulin-like growth factor I messenger RNA levels in compensatory renal hypertrophy. *Endocrinology* 20:718-724, 1987. PMID: 3803301
63. Yamashita S, **MELMED S**: Insulin-like factor-I regulation of growth hormone gene transcription in primary rat pituitary cells. *J Clin Invest* 79:449-452, 1987. PMID: 3805277 PMCID: PMC424098
64. **MELMED S**, Yamashita S, Kovacs K, Ong J, Rosenblatt S, Braunstein GD: Cushing's syndrome due to ectopic proopiomelanocortin gene expression by islet cell carcinoma of the pancreas. *Cancer* 59:(4)772-778, 1987. PMID: 3026608
65. Alexander N, **MELMED S**, Morris M: Suppressed serum prolactin levels in sino-aortic denervated rats. *Am J Physiol* 21:R290-293, 1987. PMID: 3812767

66. Fagin JA, Pixley S, Slanina S, Ong J, **MELMED S**: IGF-I gene expression in GH3 rat pituitary cells. Endocrinology 120:2037-2043, 1987. PMID: 3552629
67. Pixley S, Weiss M, **MELMED S**: Identification of human growth hormone messenger ribonucleic acid in pituitary adenoma cells by in situ hybridization. J Clin Endocrinol Metab 65:575-580, 1987. PMID: 3624415
68. Yamashita S, Ong J, **MELMED S**: Regulation of human growth hormone gene expression by insulin-like growth factor I in transfected cells. J Biol Chem 262:13254-13257, 1987. PMID: 3654610
69. Morita S, Yamashita S, **MELMED S**: IGF-I action on rat anteriorpituitary cells: Effects of intracellular messengers on growth hormone secretion and messenger RNA levels. Endocrinology 121:2000-2006, 1987. PMID: 3678137
70. Fagin S, Brown A, **MELMED S**: Regulation of pituitary IGF-I mRNA levels in rats harboring somatomammotropic tumors: implications for growth hormone autoregulation. Endocrinology 122:2204-2210, 1988. PMID: 3359980
71. Prager D, Yamashita S, **MELMED S**: Insulin regulates prolactin secretion and messenger RNA levels in pituitary cells. Endocrinology 122:2946-2952, 1988. PMID: 3286229
72. **MELMED S**, Ziel F, Braunstein GD, Downs T, Frohman LA: Medical management of ectopic production of growth hormone releasing hormone by a carcinoid tumor. J Clin Endo Metab 67 (2):395-399, 1988. PMID: 2899089
73. Prager D, **MELMED S**: Insulin regulates expression of the human growth hormone gene in transfected cells. J Biol Chem 263:16580-16585, 1988. PMID: 2903152
74. Mc Allister T, Price T, **MELMED S**: Lack of effect of naloxone on prolactin and seizures in electroconvulsive therapy. Epilepsia 30 (1):41-44, 1989. PMID: 2912716
75. Namba S, Morita S, **MELMED S**: Insulin-like growth factor I action on growth hormone secretion and mRNA levels: interaction with somatostatin. Endocrinology 124:1794-1799, 1989. PMID: 2564339
76. Barakat S, **MELMED S**: Reversible shrinkage of a growth hormone secreting pituitary adenoma by a long-acting somatostatin analog, SMS 201-995. Archives of Int Med 149:1443-1445, 1989. PMID: 2730266
77. Morita S, Fernandez C, **MELMED S**: Retinoic acid selectively stimulates growth hormone secretion and messenger ribonucleic acid levels in rat pituitary cells. Endocrinology 124:2052-2056, 1989. PMID: 2707148
78. Fagin JA, Fernandez-Mejia C, **MELMED S**: Pituitary Insulin-like growth factor I gene expression: Regulation by triiodothyronine and growth hormone. Endocrinology 125:2385-2391, 1989. PMID: 2791994
79. Siegel RJ, Fishbein MC, Said JW, Fealy M, Chai A, Rubin SA, **MELMED S**: Identification of growth hormone at the myocardial cell surface. Am J Cardiovascular Path 2:345-350, 1989. PMID: 2675936
80. Prager D, Gebremedhin S, **MELMED S**: An insulin-induced DNA-binding protein for the human growth hormone gene. J Clin Invest, 85:1680-1685, 1990. PMID: PMC296621
81. Matsuo K, Yamashita S, Niwa M, Kurihara M, Harakawa S, Izumi M, Nagataki S, **MELMED S**: Thyroid hormone regulates rat pituitary insulin-like growth factor-I receptors. Endocrinology 126:550-554, 1990. PMID: 2152872
82. Rubin SA, Buttrick P, Malhotra A, **MELMED S**, Fishbein MC: Cardiac physiology, biochemistry and morphology in response to excess growth hormone in the rat. J Mol and Cell Cardiology 22:429-438, 1990. PMID: 2143788
83. Harakawa S, Yamashita S, Tobinaga T, Matsuo K, Hirayu H, Izumi M, Nagataki S, **MELMED S**: In vivo regulation of hepatic insulin-like growth factor-I messenger ribonucleic acids with thyroid hormone. Endocrinology Japan 37:205-211, 1990. PMID: 2226339
84. Herman V, Fagin J, Gonsky R, Kovacs K, **MELMED S**: Clonal origin of pituitary adenomas. J Clin Endocrinol and Metab 71:1427-1433, 1990. PMID: 1977759

85. Herman V, Weiss M, Becker D, **MELMED S**: Hypothalamic hormonal regulation of human growth hormone gene expression in somatotroph adenoma cell cultures. Endocr Pathol 1:236-244, 1990. PMID: 32357615
86. Yamasaki H, Prager D, Gebremedhin S, Moise L, **MELMED S**: Binding and action of insulin-like growth factor I in pituitary tumor cells. Endocrinology 128:857-862, 1991. PMID: 1989866
87. Shohat M, Herman V, **MELMED S**, Neufeld N, Shrech R, Pulst S, Graham JM, Rimoin DL, Korenberg JR: Deletion of 20p 11.23 ->pter with growth hormone neurosecretory disorder but normal growth hormone releasing hormone gene. Am J Human Genetics 39:56-63, 1991. PMID: 1867266
88. Ezzat S, Laks D, Oster J, **MELMED S**: Growth hormone regulation in primary fetal and neonatal rat pituitary cell cultures: The role of thyroid hormone. Endocrinology 128:937-943, 1991. PMID: 1989871
89. Ezzat S, Strom C, **MELMED S**: Colon polyps in acromegaly. Annals Internal Medicine 114:754-755, 1991. PMID: 2012357
90. Yamasaki H, Prager D, Gebremedhin S, **MELMED S**: Insulin-like growth factor I attenuation of growth hormone is enhance by over-expression of pituitary insulin-like growth factor I receptors. Mol Endocrinol 5:890-896, 1991. PMID: 1658632
91. Ezzat S, Ren SG, Braunstein GD, **MELMED S**: Octreotide stimulates insulin-like growth factor binding protein 1 (IGFBP-1) levels in acromegaly. J Clin Endo Metab 73:441-443,1991. PMID: 1713220
92. Gonsky R, Herman VS, **MELMED S**, Fagin J: Transforming DNA sequences isolated from human prolactin-secreting pituitary tumors. Molecular Endocrinology 5:1687-1695, 1991. PMID: 1779971
93. Ren SG, Ezzat S, **MELMED S**, Braunstein GD: Somastatin analog induces insulin-like growth factor binding protein-1 (IGFBP-1) expression in human hepatoma cells. Endocrinology 131:2479-2481, 1992. PMID: 1385103
94. Weber MM, **MELMED S**, Rosenbloom J, Yamasaki H, Prager D: Rat somatotroph insulin-like growth factor II signalling: Role of the insulin-like growth factor I receptor. Endocrinology 131:2147-2153, 1992. PMID: 1425415
95. Yamasaki H, Prager D, Gebremedhin S, **MELMED S**: Human IGF-I receptor 950Tyrosine is required for somatotroph growth factor signal transduction. J Biol Chem 267:20953-20958, 1992. PMID: 1400411
96. Ezzat S, Ren SG, Braunstein GD, **MELMED S**: Octreotide stimulates IGF binding protein 1: A potential pituitary-independent mechanism for drug action. J Clin Endocrinol Metab 75:1459-1463, 1992. PMID: 1281485
97. Prager D, Yamasaki H, Weber M, Gebremedhin S, **MELMED S**: Human IGF-I receptor function in pituitary cells is suppressed by a dominant negative mutant. J Clin Invest 90:2117-2122, 1992. PMCID: PMC443280
98. Ezzat S, Snyder PJ, Young WF, Boyajy, LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM, Malarkey WB, Jackson I, Vance ML, Thorner MO, Barkan A, Frohman LA, **MELMED S**: Octreotide treatment of acromegaly a randomized, multicenter study. Ann Int Med 117:711-718, 1992. PMID: 1416572
99. Ezzat S, **MELMED S**: Endocrine applications of the somatostatin analogue octreotide (Sandostatin). Metab Clin and Exp 41:34-38, 1992. PMID: 1518431
100. Ezzat S, Ezrin C, Yamashita S, **MELMED S**: Recurrent acromegaly due to ectopic growth hormone gene expression by a metastatic pancreatic tumor. Cancer 71:66-70, 1993. PMID: 8416728
101. Prager D, Weber MM, Gebremedhin S, **MELMED S**: Interaction between insulin and thyroid hormone in rat pituitary tumor cells: insulin attenuates T3-induced growth hormone mRNA levels. J of Endocrinology 137:107-114, 1993. PMID: 8492068
102. Smith RA, **MELMED S**, Sherman B, Frane J, Munsat TL, Festoff BW: Recombinant growth hormone treatment of amyotrophic lateral sclerosis. Muscle and Nerve 16:624-633, 1993. PMID: 8502260

103. **MELMED S**: Medical management of acromegaly - what and when? Acta Endocrinol (Copenh), 129 Suppl 1:13-7, 1993. PMID: 8372605
104. Ezzat S, **MELMED S**, Endres D, Eyre DR, Singer FR: Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab, 76:1452-1457, 1993. PMID: 8501150
105. Yamasaki H, Prager D, **MELMED S**: Structure-function of the human IGF-I receptor: A discordance of somatotroph internalization and signaling. Molecular Endocrinol 7:681-685, 1993. PMID: 8316251
106. Herman V, Drazin N, Gonsky R, **MELMED S**: Molecular screening of pituitary adenomas for gene mutations and rearrangements. J Clin Endocrinol Metab 77:50-55, 1993. PMID: 8100831
107. Yamamoto H, Prager D, Yamasaki H, **MELMED S**: Rat pituitary GC cell insulin-like growth factor I receptor regulation. Endocrinology 133:1420-1425, 1993. PMID: 7689956
108. Prager D, Yamasaki H, Li J, **MELMED S**: Human insulin-like growth factor I receptor internalization role of the juxtamembrane domain. J Biol Chem 269:11934-11937, 1994. PMID: 8163493
109. **MELMED S**, Dowling RH, Frohman L, Ho K, Lamberts SWJ, LaMont JT, Sassolas G, Schoenfield L, Snyder P, Wass JAH: Consensus statement: benefits vs. risks of medical therapy for acromegaly. Am J of Med 97:468-473, 1994. PMID: 7977436
110. Greenman Y, **MELMED S**: Heterogenous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 78:398-403, 1994. PMID: 8106629
111. Pei L, **MELMED S**, Scheithauer B, Kovacs K, Prager D: H-ras mutations in human pituitary carcinoma metastases. J Clin Endocrinol Metab 78:842-846, 1994. PMID: 8157709
112. Prager D, Hsiao-Lin, Asa S, **MELMED S**: Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci 91:2181-2185, 1994. PMCID: PMC43334
113. Prager D, Yamasaki H, Weber MM, **MELMED S**: Role of the insulin-like growth factors in regulating neuroendocrine function. Neurobiology of Aging 15:569-572, 1994. PMID: 7969742
114. Greenman Y, **MELMED S**: Expression of three somatostatin receptor subtypes in pituitary adenomas: Evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79:724-729, 1994. PMID: 7521350
115. Webster J, Prager D, **MELMED S**: Insulin-like growth factor-I activation of extracellular signal-related kinase-1 and -2 in growth hormone-secreting cells. Mol Endocrinol 8:539-544, 1994. PMID: 8058064
116. Pei L, **MELMED S**: The neurofibromatosis gene in human pituitary adenomas. Endocrine Pathol 5:229-232, 1994. PMID: 32138455
117. Greenman Y, Prager D, **MELMED S**: IGF-I receptor sub-membrane is intact in GH-secreting pituitary tumors. Clin Endo 42:169-172, 1994 PMID: 7704960
118. Akita S, Webster J, Ren S-G, Takino H, Said J, Zand O, **MELMED S**: Human and murine pituitary expression of leukemia inhibitory factor (LIF) novel intrapituitary regulation of adrenocorticotropin hormone (ACTH) synthesis and secretion. J Clin Invest 95:1288-1298, 1995. PMCID: PMC441468
119. Pei L, **MELMED S**, Scheithauer B, Benedict WF, Kovacs K, Prager D: Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: Evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Research 55:1613-1616, 1995. PMID: 7712461
120. Takino H, Herman V, Weiss M, **MELMED S**: Purine-binding factor (NM23) gene expression in pituitary tumors: marker of adenoma invasiveness. J Clin Endocrinol Metab 80:1733-1738, 1995. PMID: 7745027
121. Newman CB, **MELMED S**, Snyder PJ, Young WF, Boyaji LD, Stewart WN, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook D, Malarkey WB, Jackson IMD, Van ML, Thorner MO, Ho PJ, Jaffe CA, Frohman LA, Kleinberg DL: Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients. J Clin Endocrinol Metab 80:2768-2775, 1995. PMID: 7673422

122. Pei L, **MELMED S**: Characterization of the rat vasoactive intestinal polypeptide (VIP) receptor 5' region. Biochem Journal 308:719-723, 1995. PMCID: PMC1136784
123. Rosenfeld RG, Albersson-Wikland K, Cassorla F, Douglas Frasier S, Hasegawa Y, Hintz RL, Lafranchi S, Lippe B, Loriaux L, **MELMED S**, Preece MA, Ranke MB, Reiter EO, Rogol AD, Underwood LE, Werther GA: Diagnostic Controversy: The diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab 80:1532-1540, 1995. PMID: 7538145
124. Greenman Y, Woolf P, Coniglio J, Mara RO, Pei L, Said J, **MELMED S**: Remission of acromegaly caused by pituitary carcinoma following surgical excision of GH secreting metastasis detected by 111-indium pentetreotide scan. J Clin Endocrinol Metab 81:1628-1633, 1996. PMID: 8636379
125. Faccenda E, **MELMED S**, Bevan JS, Eidne KA: Structure of the thyrotropin-releasing hormone (TRH) receptor in functional and in clinically non-functioning pituitary adenomas. Clin Endocrinology 44: 341-347, 1996. PMID: 8729534
126. Shimon I, Huttner A, Said J, Spirina OM, **MELMED S**: Heparin-binding secretory transforming gene (hst) facilitates rat lactotrope cell tumorigenesis and induces prolactin gene transcription. J Clin Invest 97:187-195, 1996. PMCID: PMC507078
127. Ray DW, Ren S-G, **MELMED S**: Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line: role of stat pathway. J Clin Invest 97:1852-1859, 1996. PMCID: PMC507253
128. Akita S, Malkin J, **MELMED S**: Disrupted murine leukemia inhibitory factor (LIF) gene attenuates adrenocorticotrophic hormone (ACTH) secretion. Endocrinology 137:3140-3143 1996. PMID: 8770940
129. Wang Z, Song-Guang R, **MELMED S**: Hypothalamic and pituitary leukemia inhibitory factor gene expression in vivo: a novel endotoxin-inducible neuro-endocrine interface. Endocrinology 137:2947-2953, 1996. PMID: 8770918
130. Stefana B, Ray DW, **MELMED S**: Leukemia inhibitory factor (LIF) induces differentiation of pituitary corticotroph function: an immuno-neuroendocrine phenotypic switch. Proc Nat Acad Sci 93:12502-12506, 1996. PMCID: PMC38021
131. Akita S, Conn PM, **MELMED S**: Leukemia inhibitory factor (LIF) induces acute adrenocorticotrophic hormone (ACTH) secretion in fetal rhesus macaque primates: A novel dynamic test of pituitary function. J Clin Endocrinol Metab 81:4170-4173, 1996.
132. Shohat M, Tick D, Barakat S, Bu X, **MELMED S**, Rimoin DL: Short-term recombinant human growth hormone treatment increases growth rate in achondroplasia. J Clin Endocrinol Metab 81:4033-4037, 1996. PMID: 8923856
133. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, Coy DH, Culler MD, **MELMED S**: Somatostatin receptor subtype specificity in human fetal pituitary cultures: Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone and prolactin regulation. J Clin Invest 99:789-798, 1997. PMCID: PMC507864
134. Pei L, **MELMED S**: Isolation and characterization of a pituitary tumor transforming gene (PTTG). Mol Endocrinol, 11:433-441, 1997. PMID: 9092795
135. Bousquet C, Ray DW, **MELMED S**: A common proopiomelanocortin binding element mediates leukemia inhibitory factor and corticotropin releasing hormone transcriptional synergy. J Biol Chem, 272:10551-10557, 1997. PMID: 9099700
136. Akita S, Readhead C, Stefanescu L, Fine J, Tampanaru-Sarmesin A, Kovacs K, **MELMED S**: Pituitary-directed leukemia inhibitory factor transgene forms Rathke's cleft cysts and impairs adult pituitary function: A model for human pituitary Rathke's cysts. J Clin Invest, 99:2462-2469, 1997. PMCID: PMC508087
137. Shimon I, Yan X, Ray DW, **MELMED S**: Cytokine-dependent gp130 receptor subunit regulates human fetal pituitary adrenocorticotropin hormone and growth hormone secretion. J Clin Invest, 100:357-363, 1997. PMID: 9218512 PMCID: PMC508198

138. Shimon I, Yan Xinmin, Taylor J., Weiss MH, Culler MD, **MELMED S**. Somatostatin Receptor (SSTR) Subtype-Selective Analogues Differentially Suppress in vitro Growth Hormone and Prolactin in Human Pituitary Adenomas: Novel Potential Therapy for Functional Pituitary Tumors. J Clin Invest 100:2386-2392, 1997. PMID: 9410919 PMCID: PMC508437
139. Wang Z, **MELMED S**: Identification of an upstream enhancer within a functional promoter of the human leukemia inhibitory factor receptor gene and its alternative promoter usage. J Biol Chem, 272:27957-27965, 1997. PMID: 9346946
140. Shimon I, **MELMED S**: Structure and function of somatostatin receptors in growth hormone control. Endocrinology 155:S3-S6, 1997. PMID: 9389989
141. Ren SG, **MELMED S**, Braunstein GD: Decidual leukemia inhibitory factor production and action on human chorionic gonadotropin secretion at different stages of gestation in vitro. Early Pregnancy: Biology and Medicine 3: 102-108, 1997. PMID: 9429850
142. Shimon I, **MELMED S** Human fetal pituitary expresses functional growth hormone-releasing peptide receptors. J Clin Endocrinol Metab 83:174-178, 1998. PMID: 9435437
143. Bonert V, Seliverstov M, **MELMED S**: Pregnancy in acromegaly: Successful therapeutic outcome. J Clin Endocrinol Metab, 83:727-731, 1998. PMID: 9506716
144. Shimon I, Hinton DR, Weiss MH, **MELMED S**: Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: Marker of tumor invasiveness. Clin Endocrinol, 48:23-29, 1998. PMID: 9509064
145. Prezant TR, Levine J, **MELMED S**: Molecular characterization of the MEN-1 tumor suppressor gene in sporadic pituitary tumors. J Clin Endocrinol Metab, 83:1388-1391, 1998. PMID: 9543172
146. Ren S-G, Seliktar J, Li X, Braunstein GD, **MELMED S**: Measurement of leukemia inhibitory factor in biological fluids by radioimmunoassay. J Clin Endocrinol Metab 83:1275-1283, 1998. PMID: 9543156
147. Chesnokova V, Auernhammer C, **MELMED S**: Murine leukemia inhibitory factor (LIF) gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response. Endocrinology 139:2209-2216, 1998. PMID: 9564824
148. Auernhammer C, Chesnokova V, **MELMED S**: Leukemia inhibitory factor (LIF) modulates IL-1 β induced activation of the hypothalamo-pituitary-adrenal axis. Endocrinology 139:2201-2208, 1998. PMID: 9564823
149. Takeuchi S, Koeffler P, Minton D, Miyoshi I, **MELMED S**, Shimon I: Mutation and expression analysis of the cycline dependent-kinase inhibitor gene p27 KIP1 in pituitary tumors. J Endocrinology 157:337-341, 1998. PMID: 9659297
150. Auernhammer C, Chesnokova V, Bousquet C, **MELMED S**: Pituitary corticotroph SOCS-3: novel intracellular regulation of cytokine-mediated POMC gene expression and ACTH secretion. Molecular Endocrinol 12:954-961, 1998. PMID: 9658400
151. **MELMED S**, Jackson I, Kleinberg D, Klibanski A: Current treatment guidelines for Acromegaly. J Clin Endocrinol Metab, 83:2646-2652, 1998. PMID: 9709926
152. Newman C, **MELMED S**, George A, Torigian D, Duhaney M, Snyder S, et al: Octreotide as primary therapy for acromegaly. J Clin Endocrinol & Metab, 83:3034-3040, 1998. PMID: 9745397
153. Drange M, **MELMED S**: Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated carcinoid. J Clin Endocrinol Metab, 83:3104-3109, 1998. PMID: 9745411
154. Shimon I, **MELMED S**: Management of pituitary tumors. Annals of Internal Medicine, 129:472-483, 1998. PMID: 9735086
155. Wang Z, **MELMED S**: Functional map of a placenta specific enhancer of the human leukemia inhibitory factor receptor gene. J Biol Chem, 273:26069-26077, 1998. PMID: 9748286

156. Shimon I, Yan X, Magoffin DA, Friedman T, **MELMED S**: Intact leptin receptor is selectively expressed in human fetal pituitary and pituitary adenomas and signals human fetal pituitary growth hormone secretion. *J Clin Endocrinol Metab*, 83:4059-4064, 1998. PMID: 9814492
157. Yano H, Readhead C, Nakashima M, Ren S-G, **MELMED S**: Pituitary-directed leukemia inhibitory factor transgene causes Cushing's syndrome: Neuro-immune endocrine modulation of pituitary development. *Molecular Endocrinology*, 12:1708-1720, 1998. PMID: 9817597 PMID: 9817597
158. Zhang X, Horwitz G, Heaney T, Nakashima M, Prezant TR, Bronstein M, **MELMED S**: Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas: marker for functional tumor invasiveness. *J Clin Endocrinol Metab*, 84:761-767, 1999. PMID: 10022450
159. Zhang X, Horwitz G, Prezant T, Valentini T, Bronstein M, **MELMED S**: Structure, expression and function of human pituitary tumor transforming gene (PTTG). *Mol Endocrinol*, 13:156-166, 1999. PMID: 9892021
160. Gadelha MR, Prezant TR, Une KN, Glick RA, Moskal SF, Vaisman M, **MELMED S**, Kineman RD, Frohman LA: Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I (Men-I) gene. *J Clin Endocrinol Metab*, 84:249-256, 1999. PMID: 9920092
161. Prezant T, Kadioglu P, **MELMED S**: An intronless homolog of human proto-oncogene hPTTG is expressed in pituitary tumors: Evidence for hPTTG family. *J Clin Endocrinol Metab*, 84:1149-1152, 1999. PMID: 10084610
162. Auernhammer C, **MELMED S**: Interleukin-11 stimulates POMC gene expression and ACTH secretion in corticotroph cells: evidence for a redundant cytokine network in the HPA axis. *Endocrinology*, 140:1559-1566, 1999. PMID: 10098488
163. Bousquet C, **MELMED S**: Critical role for STAT3 in murine pituitary ACTH leukemia inhibitory factor (LIF) signaling. *J Biol Chem*, 274:10723-10730, 1999. PMID: 10196143
164. Auernhammer C, Bousquet C, **MELMED S**: Autoregulation of pituitary corticotroph SOCS-3 expression-characterization of the murine SOCS-3 promoter. *Proc Natl Acad Sci*, 96:6964-6969, 1999. PMID: 10359822 PMCID: PMC22025
165. Tran A, Kovacs K, Stefanescu L, Kontogeorgos G, Scheithauer BW, **MELMED S**: Expression of leukemia inhibitory factor in craniopharyngioma. *Endo Path* 10(2): 103-108, 1999. PMID: 27519214
166. Ren S-G, Seliktar J, Li X, Hershmann J, Braunstein GD, **MELMED S**: In vivo and in vitro regulation of thyroid leukemia inhibitory factor (LIF) marker of hypothyroidism. *J Clin Endocrinol & Metab* 84:2883-2887, 1999. PMID: 10443695
167. **MELMED S**: Insulin-like growth factor I – a prototypic peripheral-paracrine hormone? *Endocrinology* 140:3879-3880, 1999. PMID: 10465255
168. Bousquet C, Susini C, **MELMED S**: Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor. *J Clin Invest* 104:1277-1285, 1999. PMID: 10545526 PMCID: PMC409825
169. Heaney AP, Horwitz GA, Wang Z, Singson R, **MELMED S**. Early involvement of estrogen-induced pituitary tumor transforming gene (PTTG1) and fibroblast growth factor (bFGF) expression in prolactinoma pathogenesis. *Nature Medicine* 5:1317-1321, 1999. PMID: 10546001
170. Drange M, **MELMED S**: Molecular pathogenesis of acromegaly. *Pituitary*, 2:43-50, 1999. PMID: 11081171
171. Meisel SR, Shimon I, Edgington TS, **MELMED S**, Cercek B, Shah PK: Leukaemia inhibitory factor enhances tissue factor expression in human monocyte-derived macrophages: a gp130-mediated mechanism. *Br J Haematology* 107: 747-755, 1999. PMID: 10606879
172. Drange MR, Fram NR, Bonert VH, **MELMED S**: Pituitary tumor registry: A novel clinical resource. *J Clin Endocrinol Metab*, 85:168-174, 2000. PMID: 10634382
173. Wang Z, **MELMED S**: Characterization of the murine pituitary tumor transforming gene (PTTG) gene and its promoter. *Endocrinology*, 141:763-771, 2000. PMID: 10650958

174. Heaney A, **MELMED S**, Singson R, McCabe CJ, Nelson V, Nakashima M: Expression of pituitary tumor transforming gene in colorectal tumors. Lancet 355:716-719, 2000. PMID: 10703804
175. Giustina A, Barkan A, Casanueva F, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass, von Werder J, **MELMED S**: Criteria for cure of acromegaly: A consensus statement, J Clin Endocrinol Metab, 85:526-529, 2000. PMID: 10690849
176. Wang Z, **MELMED S**: Pituitary tumor transforming gene (PTTG) transforming and transactivation activity. J Biol Chem 275:7459-7461, 2000. PMID: 10713046
177. Yu R, Ren S-G, Wang Z, Horwitz G, **MELMED S**: The pituitary tumor transforming gene (PTTG) regulates cells survival and division; evidence from live cell imaging. Mol Endo, 14:1137-1146, 2000. PMID: 10935539
178. Kontogeorgos G, Patralexis H, Tran A, Kovacs K, **MELMED S**: Expression of leukemia inhibitory factor in human pituitary adenomas: a morphologic and immunocytochemical study. Pituitary 2:245-251, 2000. PMID: 11081145
179. Bonert VH, Zib K, Scarlett JA, **MELMED S**: Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab, 85: 2958-2961, 2000. PMID: 10946911
180. Maheshwari HG, Herman-Bonert V, Shahinian H, Kovacs K, **MELMED S**: Long acting peptidomergic control of gigantism caused by acidophilic stem cell adenoma. J Clin Endocrinol Metab, 85:3409-3416, 2000. PMID: 10999842
181. Bousquet C, Zatelli MC, **MELMED S**: Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing. J Clin Invest 106: 1417-1425, 2000. PMID: 11104795 PMCID: PMC381469
182. Chesnokova V, **MELMED S**: Leukemia inhibitory factor (LIF) mediates the hypothalamic pituitary adrenal axis response to inflammation. Endocrinology 141:4032-4040, 2000. PMID: 11089533
183. Stefanescu L, Kovacs K, Thapar K, Horvath E, **MELMED S**, Greenman Y: Octreotide effect on growth hormone and somatostatin subtype 2 receptor mRNAs of the human pituitary somatotroph adenomas. Endocrine Path 11:41-48, 2000. PMID: 12114656
184. Yu R, Heaney AP, Lu W, Chen J, **MELMED S**: Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J Biol Chem, 275:36502-36505, 2001. PMID: 11013229
185. Ishikawa H, Heaney AP, Yu R, Horwitz G, **MELMED S**: Human pituitary tumor transforming gene (PTTG) induces angiogenesis. J Clin Endocrinol Metab, 86:867-874, 2001. PMID: 11158059
186. Yu R, **MELMED S**: Oncogene activation in pituitary tumors. Brain Pathology, 11:328-341, 2001. PMID: 11414475
187. Rubinek T, Hadani M, Barkai G, **MELMED S**, Shimon I: Prolactin (PRL)-releasing peptide stimulates prolactin secretion from human fetal pituitary cultures and growth hormone release from cultured pituitary adenomas. J Clin Endocrinol Metab, 86:2826-2830, 2001. PMID: 11397894
188. **MELMED S**: Acromegaly and Cancer: not a problem. J Clin Endocrinol Metab, 86:2929-34, 2001. PMID: 11443145
189. Bousquet C, Chesnokova V, Kariagina A, Ferrand A, **MELMED S**: cAMP neuropeptide agonists induce pituitary suppressor of cytokine signaling-3: novel negative feedback mechanism for corticotroph cytokine action. Mol Endo, 15(11):1880-1890, 2001. PMID: 11682619
190. Wang Z, Yu R, **MELMED S**: Mice lacking pituitary tumor transforming gene (PTTG) show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression and premature centromere division, Mol Endo 15:1870-1879, 2001. PMID: 11682618
191. Auernhammer CJ, **MELMED S**: The central role of SOCS-3 in integrating the neuro-immunoendocrine interface. J Clin Invest, 108:1735-1740, 2001. PMID: 11748254 PMCID: PMC209479
192. van der Lely A, Hutson K, Trainer PJ, Besser M, Barkan A, et al: Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist, Lancet, 2001. PMID: 11734231

193. Bode JG, Ludwig S, Freitas CA, Schaper F, Ruhl M, **MELMED S**, Heinrich PC, Haussinger D. The MKK6/p38 mitogen activated protein kinase pathway is capable of inducing SOCS3 gene expression and inhibits IL-6 induced transcription. Biol Chem 382:1447-1453, 2001. PMID: 11727828
194. Ben Shlomo A, **MELMED S**: Growth hormone excess and cancer. J Anti-Aging Med 4:373-381, 2001.
195. Heaney A, **MELMED S**: Functional role of estrogen receptor in pituitary tumor pathogenesis, J Clin Invest, 109:277-283, 2002. PMID: 11805140 PMCID: PMC150842
196. Chesnokova V, Kariagina A, **MELMED S**: Opposing effects of pituitary leukemia inhibitory factor and SOCS-3 on the ACTH axis response to inflammation. Am J Physiology, 282:E1110-E1118, 2002. PMID: 11934677
197. **MELMED S**, Casanueva F, Cavagnini F, Chanson P, Frohman L, Giordano G, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Pinchera A, Serio M, Vance ML, Vigneri R, Wass J, von Werder K, Giustina A. Guidelines for acromegaly management: a consensus statement. J Clin Endocrinol Metab, 87:4054-4058, 2002. PMID: 12213843
198. Yu R, Song-Guang R, **MELMED S**: Proteasome inhibitors induce apoptosis in GH- and PRL-secreting rat pituitary tumor cells. Journal of Endocrinology, 174:379-386, 2002. PMID: 12208657
199. Heaney AP, Fernando M, Yong W, **MELMED S**: Functional PPAR- γ Receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas, Nature Medicine, 8:1281-1287, 2002. PMID: 12379847
200. Stoika, RS, Yu R, **MELMED S**: Expression and function of pituitary tumour transforming gene (PTTG) for T-lymphocyte activation. British Journal of Haematology, 119:1070-1074, 2002. PMID: 12472590
201. Kontogeorgos G, Scheithauer BW, Kovacs KK, Horvath E, **MELMED S**: Growth factors and cytokines in paragangliomas and pheochromocytomas, with a special reference to the sustentacular cells. Endocrine Pathology, 13: 192-206, 2002. PMID: 12446918
202. **MELMED S**, Vance ML, Barkan AL, Bengtsson B-A, Kleinberg D, Klibanski A, Trainer PJ: Current status and future opportunities for controlling acromegaly. Pituitary, 5:185-196, 2002. PMID: 12812311
203. Chesnokova V, **MELMED S**: Minireview: Neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules. Endocrinology 143:1571-1574, 2002. PMID: 11956136
204. Ben-Shlomo A, Miklovsy I, Ren S-G, Yong WH, Heaney AP, Culler MD, **MELMED S**: Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells, J Clin Endocrinol and Metab, 88:858-63, 2003. PMID: 12574225
205. Horwitz GA, Miklovsy I, Heaney AP, Ren S-G, **MELMED S**: Human pituitary tumor transformation gene (PTTG1) motif suppresses prolactin expression. Mol Endo 17:600-609, 2003. PMID: 12554778
206. Wang Z, Moro E, Kovacs K, Yu R, **MELMED S**: Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes. Proc Natl Acad Sci 100:3428-32, 2003. PMID: 12626748 PMCID: PMC152309
207. Heaney AP, Fernando M, **MELMED S**: PPAR- γ receptor ligands: novel therapy for pituitary adenomas. J Clin Invest, 111:1381-8, 2003. PMID: 12727930 PMCID: PMC154441
208. Liu N-A, Huang H, Yang Z, Herzog W, Hammerschmidt M, Lin S, **MELMED S**: Pituitary corticotroph ontogeny and regulation in transgenic zebrafish. Mol Endo, 17:959-966, 2003. PMID: 12576489
209. Ren SG, Kim S, Taylor J, Dong J, Moreau J-P, Culler M, **MELMED S**: Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab, 88:5414-21, 2003. PMID: 14602782
210. Yu R, Lu W, **MELMED S**: Overexpressed pituitary tumor transforming gene (PTTG) cause aneuploidy in live human cells. Endocrinology, 144:4991-4998, 2003. PMID: 12960092

211. Ren SG, Taylor J, Dong J, Yu R, Culler MD, **MELMED S**: Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. *J Clin Endocrinol and Metab* 88:4239-45, 2003. PMID: 12970293
212. Clemmons DR, Chihara K, Freda PU, Ho KK, Klibanski A, **MELMED S**, Shalet SM, Strasburger CJ, Trainer PJ, Thorner MO: Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. *J Clin Endocrinol Metab* 88:4759-67, 2003. PMID: 14557452
213. Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, et al: Diagnosis and treatment of acromegaly complications. *J Endocrinol Invest* 26:1242-47, 2003. PMID: 15055479
214. Abbud RA, Kelleher R, **MELMED S**: Cell specific pituitary gene expression profiles after treatment with leukemia inhibitory factor reveal novel modulators for POMC expression. *Endocrinology*, 145:867-880, 2004. PMID: 14576184
215. Bonert VB, **MELMED S**: Body mass index determines evoked GH responsiveness in normal health male subjects: Diagnostic caveat for adult GH deficiency. *J Clin Endocrinol Metab*, 89:3397-3401, 2004. PMID: 15240621
216. Murray RD, Kim K, Ren S-G, Chelly M, Umerhara Y, **MELMED S**: Central and peripheral actions of somatostatin on the growth hormone-insulin-like growth factor-I axis. *J Clin Investigation*, 114:349-356, 2004. PMID: 15286801 PMCID: PMC484973
217. Murray RD, Kim K, Ren SG, Lewis I, Weckbecker G, Bruns G, **MELMED S**: The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. *J Clin Endocrinol Metab*, 89:3027-3032, 2004. PMID: 15181094
218. Ben-Shlomo A, Herman-Bonert V, **MELMED S**: Pegvisomant: the role of a growth hormone receptor antagonist in the treatment of acromegaly. *Curr Opin in Endo and Diab*. 11:276-280, 2004.
219. Boelaert K, Yu R, Tannahill L, Stratford AL, Khanim FL, Eggo MC, Moore JS, Young LS, Gittoes NJ, Franklyn JA, **MELMED S**, McCabe CJ. PTTG's c-terminal PXXP motifs modulate critical cellular processes in vitro. *J Mol Endocrinol* 33:663-77, 2004. PMID: 15591026
220. Abbud A, Barker EM, Takumi I, Ren SG, Chen DY, Wawrowsky K, **MELMED S**: Early multipotential pituitary focal hyperplasia in the α -subunit of glycoprotein hormone-driven pituitary tumor transforming gene transgenic mice. *Mol Endo*, 19:1383-91, 2005. PMID: 15677710
221. Chesnokova V, Kovacs K, Castro A-V, Alon D, **MELMED S**: PTTG hypoplasia in PTTG -/- mice is protective for Rb +/- pituitary tumorigenesis. *Mol Endo*, 19:2371-2379, 2005. PMID: 15919720 PMCID: PMC1201444
222. Ben-Shlomo A, Wawrowsky KA, Miklovsky I, Ren SG, Taylor J, Culler MD, **MELMED S**: Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of ACTH secretion. *J Biol Chem* 280:24011-21, 2005. PMID: 15857828
223. **MELMED S**, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A: A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. *J Clin Endo Metab*, 90:4405-4410, 2005. PMID: 15827109
224. **MELMED S**. Pharmacologic treatment of acromegaly. *Medscape Clinical Update* (e-pub), 2005.
225. Akino K, Akita S, Mizuguchi T, Takumi I, Yu R, Wang XY, Roxga J, Demetriou AA, **MELMED S**, Ohtsuru A, Yamashita S. A novel molecular marker of pituitary tumor transforming gene involves in rat liver regeneration. *J Surg Res* 129:142-146, 2005. PMID: 15936773
226. **MELMED S**, Casanueva F, Cavagnini P, Chanson P, Frohman LA, Laws E, Gaillard R, Ghigo E, Ho K, Kleinberg D, Jacquet P, Lamberts S, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JAH, Giustina A. Consensus statement: medical management of acromegaly. *Eur J of Endo* 153:737-40, 2005. PMID: 16322377
227. Donangelo I, **MELMED S**: Treatment of acromegaly: future. *Endocrine* 28:123-8, 2005. PMID: 16311419
228. Donangelo I, **MELMED S**: Pathophysiology of pituitary adenomas. *J Endocrinol Invest* 28:100-105, 2005. PMID: 16625857

229. Liu N-A, Liu Q, Wawrowsky K, Yang Z, Lin S, **MELMED S**: Prolactin receptor signaling mediates the osmotic response of embryonic zebrafish lactotroph. *Mol Endocrinology*, 20:871-80, 2006. PMID: 16339273
230. Yu R, Bonert V, Cruz-Soto M, **MELMED S**: Comment: Cyclin-dependent kinase inhibitor gene polymorphisms in pituitary gigantism. *Endocrine* 29:119-120, 2006. PMID: 16622299
231. **MELMED S**: 2004 World Health Organization classification of pituitary tumors: what is new? *Acta Neuropathol* 111:78-79, 2006. PMID: 16328519
232. Gillingwater TH, Wishart TM, Chen PE, Haley JE, Robertson K, MacDonald SH, Middleton S, Wawrowski K, Shipston MJ, **MELMED S**, Wyllie DJ, Skehel PA, Coleman MP, Ribchester RR: The neuroprotective WldS gene regulates expression of PTTG1 and erythroid differentiation regulator 1-like gene in mice and human cells. *Hum Mol Genet* 15:625-635, 2006. PMID: 16403805
233. Donangelo I, **MELMED S**: Implication of pituitary tropic status on tumor development. *Front Horm Res* 35:1-8, 2006. PMID: 16809918
234. Bronstein MD, **MELMED S**: Pituitary tumorigenesis. *Arg Bras Endocrinol Metab* 49:615-625, 2006. PMID: 16444345
235. Lum PY, Chen Y, Zhu J, Lamb J, **MELMED S**, Wang S, Drake TA, Lusk AJ, Schadt EE: Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetes. *J Neurochem*, Supplement (97) 1:50-62, 2006. PMID: 16635250
236. Akita S, Akino K, Ren SG, **MELMED S**, Imaizumi T, Hirano A: Elevated circulating leukemia inhibitory factor in patients with extensive burns. *J Burn Care Res*, 27:221-225, 2006. PMID: 16566572
237. Ren S-G, **MELMED S**: Pyridoxal phosphate inhibits pituitary cell proliferation and hormone secretion. *Endocrinology* 147:3936-3942, 2006. PMID: 16690808 PMCID: PMC1513048
238. Bonert VH, **MELMED S**: Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. *Nat Clin Prac Endo and Metab* 2:408-12, 2006. PMID: 16932323
239. Fraenkel M, Caloyeras J, Ren SG, **MELMED S**: Sex-steroid milieu determines diabetes rescue in pttg-null mice. *J Endocrinol* 189:519-528, 2006. PMID: 16731783
240. Donangelo I, Gutman S, Horvath E, Kovacs K, Wawrowsky K, Mount M, **MELMED S**: PTTG over-expression facilitates pituitary tumor development. *Endocrinology* 147:4781-4791, 2006. PMID: 16809444
241. Liu NA, Liu Q, Wawrowsky K, Yang Z, Lin S, **MELMED S**: Prolactin receptor signaling mediates the osmotic response of embryonic zebrafish lactotrophs. *Mol Endocrinol* 20:871-880, 2006. PMID: 16339273
242. Yu R, Bonert V, Saporta I, Raffel LJ, **MELMED S**: Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas. *J Clin Endocrinol & Metab*, 91:5126-5129, 2006. PMID: 17018653
243. Ben-Shlomo A, **MELMED S**: Skin manifestations in acromegaly. *Clinics in Dermatology in Endocrinology and the Skin*, Vol. 24, pp. 256-259, 2006. PMID: 16828406
244. Vlotides G, Cruz-Soto M, Rubinek T, Eigler T, Auernhammer C, **MELMED S**: Mechanisms for growth factor-induced pituitary tumor transforming gene-1 (PTTG1) expression in pituitary folliculostellate TtT/GF cells. *Mol Endo* 20:3321-3335, 2006. PMID: 16959877
245. Tong Y, Tan Y, Zhou C, **MELMED S**: Pituitary tumor transforming gene interacts with SP1 to modulate G1/S cell phase transition. *Oncogene*, 26:5596-5605, 2007. PMID: 17353909 PMCID: PMC2736684
246. **MELMED S**: Aryl hydrocarbon receptor interacting protein and pituitary tumorigenesis: Another Interesting Protein. *J Clin Endocrinol Metab*, 92:1617-1619, 2007. PMID: 17483376
247. Ben-Shlomo A, **MELMED S**: Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation. *Mol Endo*, 21:2565-2578, 2007. PMID: 17609435

248. Rubinek T, Wolf I, Chesnokova V, Vlotides G, **MELMED S**: Discordant proliferation and differentiation in pituitary transforming gene-null bone marrow stem cells. *Am J Physiol* 293:C1082-1092, 2007. PMID: 17626243
249. Gruszka A, Ren S-G, Dong J, Culler MD, **MELMED S**: Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. *Endocrinology*, 148:6107-6114, 2007. PMID: 17656461
250. Chesnokova V, Zonis S, Rubinek T, Yu R, Ben-Shlomo A, Kovacs K, Wawrowsky K, **MELMED S**: Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. *Cancer Res*, 67:10564-10572, 2007. PMID: 17975001 PMCID: PMC2770267
251. Ben-Shlomo A, **MELMED S**: Drug profile: Pasireotide- a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. *IDrugs* 10:885-895, 2007. PMID: 18041687
252. Melmed GY, Yu R, Vlotides G, Ross G, Soraya A, Devlin S, **MELMED S**: Anti-aging therapy with human growth hormone associated with metastatic colon cancer in a patient with Crohn's colitis". *Clin Gastr and Hepat*, 6:360-363, 2008. PMCID: PMC2696478
253. **MELMED S**: Update in Pituitary Disease, *J Clin Endocrinol and Metab* 93:331-338, 2008. PMID:18258780
254. Cooper O, Geller J, **MELMED S**: Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenoma. *Nat Clin Pract Endo & Metab*, 4:234-238, 2008. PMCID: PMC2777809
255. Liu N-A, Ren M, Song J, Rios Y, Wawrowsky K, Ben-Shlomo A, Lin S, **MELMED S**: In vivo time-lapse imaging delineates the zebrafish pituitary proopiomelanocortin lineage boundary regulated by FGF3 signal. *Developmental Biology*, 319:192-200, 2008. PMCID: PMC2583244
256. Murray RD, **MELMED S**: A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. *J Clin Endocrinol Metab*, 93:2957-2968, 2008. PMID: 18477663
257. Ben-Shlomo A, **MELMED S**: Somatostatin agonists for treatment of acromegaly. *Mol and Cell Endocrinol*, 286:192-208, 2008. PMCID: PMC2697610
258. Vlotides G, Siegel E, Donangelo I, Gutman S, Ren S-G, **MELMED S**: Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. *Cancer Res*, 68:6377-6386, 2008. PMCID: PMC2497431
259. Zhou C, Tong Y, Wawrowsky K, Bannykh S, Donangelo I, **MELMED S**: Oct-1 induces human pituitary tumor transforming gene (hPTTG1) expression in endocrine tumors. *Endocrine-Related Cancer*, 15:817-831, 2008. PMCID: PMC3123374
260. Tong Y, Ben-Shlomo A, Zhou C, Wawrowsky K, **MELMED S**: Pituitary tumor transforming gene (PTTG1) modulates Aurora Kinase A activity. *Oncogene* 27:6385-95, 2008. PMID: 18663361
261. Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J, **MELMED S**: Lipodystrophy in patients with acromegaly receiving pegvisomant. *J Clin Endocrinol Metab* 93:3515-3518, 2008. PMID:18611977
262. Giustina A, Barkan A, Chanson P, Grossman A, Hoffman A, Ghigo E, Casanueva F, Colao A, Lamberts S, Sheppard M, **MELMED S**: Pituitary Society, European Neuroendocrine Association. Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. *J Endo Invest*, 31:820-838, 2008. PMID:18997495
263. Chesnokova V, Zonis S, Kovacs K, BenShlomo A, Wawrowsky K, Bannykh S, **MELMED S**: p21Cip1/Kip1 restrains pituitary tumor growth. *Proc Natl Acad Sci* 105:17498-17503, 2008. PMCID: PMC2577704
264. Biller BM, Grossman AB, Stewart PM, **MELMED S**, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. *J Clin Endocrinol Metab* 93:2454-2462, 2008. PMCID: PMC3214276

265. Webb SM, Strasburger CJ, Mo D, Harman ML, **MELMED S**, Jung H, Blum WF, Attanasio AF: on behalf of the HypoCCS international Advisory Board. Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database. J Clin Endocrinol Metab, 94:392-399, 2009. PMID: 19001512
266. glucose tolerance testing (OGTT) for diagnosis and assessment of treatment outcomes in 170 patients with acromegaly. J Clin Endocrinol Metab, 94:523-527, 2009. PMID:19033371
267. Ben-Shlomo A, Zhou C, Pichurin O, Chesnokova V, Liu NA, Culler M, **MELMED S**: Constitutive somatostatin receptor activity determines tonic pituitary cell response. Mol Endo, 23:337-348, 2009. PMID: PMC2725764
268. **MELMED S**, Barkan A, Chanson P, Clemmons D, Colao A, Grossman A, Ho K, Kleinberg D, Laws E, Molitch M, Schlechte J, Vance ML, Giustina A: Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509-17, 2009. PMID: 19208732
269. Arzt E, Chesnokova V, Stalla GK, **MELMED S**: Pituitary adenoma growth: A model for cellular senescence and cytokine action, Cell Cycle 8: 677-682, 2009. PMID: PMC2710531
270. Vlotides G, Cooper O, Chen YH, Ren SG, Greenman Y, **MELMED S**: Heregulin regulates prolactinoma gene expression, Cancer Res 69:4209-4216, 2009. PMID: PMC2688701
271. Vlotides G, Chen YH, Eigler T, **MELMED S**: Fibroblast growth factor-2 auto-feedback regulation in pituitary folliculostellate Tt/GF cells, Endocrinology 150:3252-8, 2009. PMID: PMC2703553
272. Ben-Shlomo A, Schmid H, Wawrowsky K, Pichurin O, Hubina E, Chesnokova V, Liu NA, Culler M, **MELMED S**: Differential ligand-mediated pituitary somatostatin receptor subtype signalling: Implications for corticotroph tumor therapy. J Clin Endocrinol Metab, 94:4342-50, 2009. PMID: PMC2697610.
273. Zhou C, Wawrowsky K, Bannykh S, Gutman S, **MELMED S**: E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors. Mol Endocrinol, 23:2000-12, 2009. PMID: PMC2796149
274. Chesnokova V, **MELMED S**: Pituitary tumour-transforming gene (PTTG) and pituitary senescence. Horm Res 71 Suppl 2:82-87, 2009. PMID:19407503
275. Boscaro M, Ludlam WH, Atkinson B, GLusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BMK, Fiindling J, **MELMED S**, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94:115-122, 2009. PMID: 18957506
276. Webb SM, Mo D, Lamberts SWJ, **MELMED S**, Cavagnini F, Giraldi FP, Strasburger CJ, Zimmermann AG, Woodmansee WW on behalf of the International HypoCCS advisory board: Metabolic, cardiovascular and cerebrovascular outcomes in growth hormone-deficient subjects with previous Cushing's disease or non-functioning pituitary adenoma. J Clin Endocrinol Metab 95:630-8, 2010. PMID:20022992
277. **MELMED S**, Cook D, Schopohl J, Goth MI, Lam KSL, Marek J. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicentre study with a 52 week open extension. Pituitary 13:18-28, 2010. PMID: PMC2807598
278. Klibanski A, **MELMED S**, Clemmons DR, Colao A, Cunningham RS, Molitch ME, Vinik AI, Adelman DT, Liebert KJP: The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome. Pituitary, 13:266-286, 2010. PMID: PMC2913001
279. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts A, Casanueva FF, Trainer P, Ghigo E, Ho K, **MELMED S**: A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab, 95:3141-3148, 2010. PMID: 20410227
280. Cooper O, Ben-Shlomo A, Bonert V, Bannykh S, Mirocha J, **MELMED S**: Silent corticogonadotroph pituitary adenomas: clinical and cellular characteristics and long-term outcomes. Hormones and Cancer, 1:80-92, 2010. PMID: PMC2921667

281. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho Y-Y, Hu K, Farrall AJ, **MELMED S**, Biller BMK, and the Pasireotide Acromegaly Study Group: Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, Phase II trial. *J Clin Endocrinol Metab*, 95:2781-2789, 2010. PMID: 20410233
282. Ben-Shlomo A, Wawrowsky K, **MELMED S**: Constitutive activity of somatostatin receptor subtypes, *Methods Enzymol* 484:149-64, 2010. PMID:21036231
283. Yu R, **MELMED S**: Pathogenesis of pituitary tumors. *Prog Brain Res* 182:207-27, 2010. PMID:20541667
284. Chesnokova V, Zonis S, Ben-Shlomo A, Wawrowsky K, **MELMED S**: Molecular mechanisms of pituitary adenoma senescence. *Front Horm Res* 38:7-14, 2010. PMID:20616490
285. Rios Y, **MELMED S**, Lin S, Liu N-A: Zebrafish *usp39* mutation leads to *rb1* mRNA splicing defect and pituitary lineage expansion. *PLoS Genetics*, 7:1271-82, 2011. PMCID: PMC3020934
286. **MELMED S**, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JAH: Diagnosis and treatment of hyperprolactinemia: An Endocrine Society Clinical Practice Guideline, *J Clin Endocrinol Metab*, 96:273-288, 2011. PMID:21296991
287. Fukuoka H, Cooper O, Mizutani J, Tong Y, Song-Guang R, Bannykh S, **MELMED S**: HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. *Mol Endocrinol*, 25:92-103, 2011. PMCID: PMC3089034
288. Hoffman AR, **MELMED S**, Schlechte J: Patient guide to hyperprolactinemia diagnosis and treatment. *J Clin Endocrinol Metab* 96:35A-6A, 2011. PMID: 21296988
289. Chesnokova V, Zonis S, Zhou C, Ben-Shlomo A, Wawrowsky K, Toledano Y, Tong Y, Kovacs K, Scheithauer B, **MELMED S**: Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. *PLoS One*, 6(3):e17924, 2011. PMCID: PMC3064664
290. Giustina A, Bronstein MD, Casanueva FF, Chanson P, Ghigo E, Ho KK, Klibanski A, Lamberts S, Trainer P, **MELMED S**: Current management practices for acromegaly: an international survey. *Pituitary*, 14:125-33, 2011 PMID: 21213053
291. **MELMED S**: Pathogenesis of Pituitary Tumors. *Nature Reviews Endocrinology*, 7:257-266, 2011. PMID: 21423242
292. Famini P, Maya MM, **MELMED S**: Pituitary magnetic resonance imaging for sellar and parasellar masses: Ten-year experience in 2598 patients. *J Clin Endocrinol Metab*, 96:1633-41, 2011. PMID: 21470998 PMCID: PMC3100749
293. Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, **MELMED S**: Clinical, quality of life and economic value of acromegaly disease control. *Pituitary* 14:284-294, 2011. PMID: 21597975 PMCID: PMC3146976
294. Liu NA, Jiang H, Fan X-M, Ben-Shlomo A, Wawrowsky K, Lin S, **MELMED S**. Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. *Proc Natl Acad Sci*, 108:8414-9, 2011. PMID: 21536883 PMCID: PMC3100964
295. Tong Y, Zhao W, Wawrowsky K, **MELMED S**: PTTG1 attenuates drug-induced cellular senescence. *PLoS One*, 6:e23754, 2011. PMID: 21858218 PMCID: PMC3157437
296. Tong Y, Zhou J, Mizutani J, Fukuoka H, Ren S-G, Gutierrez-Hartmann A, Koeffler HP, **MELMED S**: CEBPD suppresses prolactin expression and prolactinoma cell proliferation, *Mol Endocrinol* 25:1880-91, 2011. PMID: 21980073 PMCID: PMC3198962
297. Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D, **MELMED S**: EGFR as a Therapeutic Target for human, canine, and mouse ACTH-Secreting Pituitary Adenomas. *J Clin Invest*, 121:4712-21, 2011. PMID: 22105169 PMCID: PMC3226010
298. Tong Y, Zheng Y, Zhou J, Oyesiku NM, Koeffler HP, **MELMED S**: Genomic characterization of human and rat prolactinomas. *J Clin Endocrinol Metab*, 153:3679-3691, 2012. PMID: 22635680 PMCID: PMC3404356
299. Tuvia S, Atsmon J, Teichman SL, Katz S, Salama P, Pelled D, Landau I, Karmeli I, Kramer WG, Bidlingmaier M, Strasburger CJ, Kleinberg DL, **MELMED S**, Mamluk R. Oral octreotide absorption

- in human subjects: Comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab, 97:2362-2369, 2012. PMID: 22539587
300. Cooper O, **MELMED S**: Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Practice & Research Clinical Endocrinology & Metabolism, 26:447-460, 2012. PMID: 22539587
PMCID: PMC3412996
301. Gruszka A, Culler M, **MELMED S**: Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion *in vitro*. Mol and Cell Endocrinol, 362:104-109, 2012. PMID: 22705877
302. Toledano Y, Zonis S, Song-Guang R, Wawrowsky K, Chesnokova V, **MELMED S**: Estradiol partially recapitulates murine pituitary cell cycle response to pregnancy. Endocrinology 153:5011-5022, 2012. PMID: 22851678 PMCID: PMC3512024
303. Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, **MELMED S**: Meta-analysis on the effect of octreotide on tumor mass in acromegaly. PLoS One, 7:e36411, 2012. PMID: 22574156 PMCID: PMC3344864
304. Chesnokova V, Zonis S, Wawrowsky K, Tani Y, Ben-Shlomo A, Ljubimov V, Mamelak A, Bannykh S, **MELMED S**: Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph-cell adenoma growth. Mol Endocrinol 26:2092-103, 2012. PMID: 23051594 PMCID: PMC3517712
305. Somm E, Bonnet N, Martinez A, Marks PMH, Cadd VA, Elliott M, Toulotte A, Ferrari SL, Rizzoli R, Huppi PS, Harper E, **MELMED S**, Jones R, Aubert ML. A botulinum toxin-derived targeted secretion inhibitor (TSI) inhibits rat GH/IGF-I axis: a novel therapeutic approach for acromegaly. J Clin Invest 122:3295-306, 2012. PMID: 22850878 PMCID: PMC3428092
306. Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, **MELMED S**, Sakurai A, Tonelli F, Brandi ML; Endocrine Society: Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 97:2990-3011, 2012. PMID: 22723327
307. Mamelak AN, Carmichael J, Bonert VH, Cooper O, **MELMED S**. Single-surgeon fully endoscopic endonasal transsphenoidal surgery: outcomes in three-hundred consecutive cases. Pituitary, 16:393-401, 2013. PMID: 23011322
308. Hartman ML, Xu R, Crowe BJ, Robison LL, Erfurth EM, Kleinberg DL, Zimmerman AG, Woodmansee WW, Cutler GB, Chipman JJ, **MELMED S**. Prospective safety surveillance of growth hormone (GH) deficient adults: comparison of GH-treated vs. untreated patients. J Clin Endocrinol Metab, 98:980-988, 2013. PMID: 23345098 PMCID: PMC3677286
309. Ghazi AA, Amirbaigloo A, Dezfooli AA, Saadat N, Ghazi S, Pourafkari M, Targari F, Dhall D, Bannykh S, **MELMED S**, Cooper O: Ectopic acromegaly due to growth hormone releasing hormone. Endocrine, 43:293-302, 2013. PMID: 22983831 PMCID: PMC3553305
310. **MELMED S**: Update: Idiopathic Adult Growth Hormone Deficiency. J Clin Endo Metab, 98:2187-97, 2013. PMID: 23539718 PMCID: PMC3667267
311. Ben-Shlomo A, Pichurin O, Khalafi R, Zhou C, Chesnokova V, Ren S-G, Liu NA, **MELMED S**. Constitutive somatostatin receptor subtype 2 activity attenuates GH synthesis. Endocrinology 154:2399-409, 2013. PMID: 23696564 PMCID: PMC3689284
312. **MELMED S**, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JAH, Giustina A: A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16:294-302, 2013. PMID: 22903574 PMCID: PMC3730092
313. Chesnokova V, Zhou C, Zonis S, Tani Y, Ben-Shlomo A, Ren SG, **MELMED S**: Growth hormone is a cellular senescence target in pituitary and non-pituitary cells. Proc Natl Acad Sci 110(35):E3331-9, 2013. PMID: 23940366 PMCID: PMC3761588
314. Petersenn S, Webber D, Farrall A, DeBlock C, **MELMED S**, Schopohl J, Caron P, Cuneo R, Kleinberg D, Colao AM, Barkan A. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. Pituitary, 17:132-140, 2014. PMID: 23529827 PMCID: PMC3942632

315. Zhou C, Tong Y, Wawrowsky K, **MELMED S**: PTTG acts as a STATs target gene for colorectal cancer cell growth and motility. *Oncogene* 33:851-61, 2014. PMID: 23416975 PMCID: PMC3930149
316. Donangelo I, Ren SG, Eigler T, Svendsen C, **MELMED S**: Sca+ murine pituitary adenoma cells show tumor growth advantage. *Endocr Relat Cancer* 21:203-216, 2014. PMID: 24481638 PMCID: PMC3978815
317. Carmichael JD, Bonert V, Nuno M, Ly D, **MELMED S**: Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. *J Clin Endocrinol Metab*, 99:1825-1833, 2014. PMID: 24606084 PMCID: PMC4010703
318. Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons D, Klibanski A, Van der Lely AJ, Strasburger CJ, Lamberts SW, Ho, Casanueva FF, **MELMED S**: Expert consensus document: A consensus on the medical treatment of acromegaly. *Nat Revs Endocrinol*, 10:243-248, 2014. PMID: 24566817
319. Ben-Shlomo A, Mirocha J, Gwin SM, Khine AK, Liu NA, Sheinin RC, **MELMED S**: Clinical factors associated with biochemical adrenal-cortisol insufficiency in hospitalized patients. *Am J of Med*, 127:754-762, 2014. PMID: 24632056 PMCID: PMC4127354
320. Eigler T, Ben-Shlomo A, Zhou C, Khalfai R, Ren SG, **MELMED S**: Constitutive somatostatin receptor subtype-3 signaling suppresses growth hormone synthesis. *Mol Endocrinol*, 28:554-64, 2014. PMID: 24606125 PMCID: PMC3968402
321. Keeley PW, Zhou C, Lu L, Williams RW, **MELMED S**, Reese BE: Pituitary tumor-transforming gene 1 regulates the patterning of retinal mosaics. *Proc Natl Acad Sci*, 111:9295-300, 2014. PMID: 24927528 PMCID: PMC4078852
322. Katznelson L, Laws Jr ER, **MELMED S**, Molitch ME, Utz A, Wass JA: Acromegaly: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*, 99(11):3933-51, 2014. PMID: 25356808
323. Mo D, Hardin DS, Erfurth EM, **MELMED S**: Adult mortality or morbidity is not increased in childhood-onset growth hormone deficient patients who received pediatric GH treatment: an analysis of the Hypopituitary control and complications study (HypoCCS). *Pituitary* 17(5) 477-85, 2014. PMID: 24122237 PMCID: PMC4159575
324. Cuevas-Ramos D, Carmichael JD, Cooper O, Bonert VH, Gertych A, Mamelak AN, **MELMED S**: A structural and functional acromegaly classification. *J Clin Endocrinol Metab*, 100:122-31, 2015. PMID: 25250634 PMCID: PMC4283008
325. Liu X, Kano M, Takako A, Cooper O, Fukuoka H, **MELMED S**: ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice. *Endocrinology*, 156:71-79, 2015. PMID: 25375038 PMCID: PMC4272404
326. **MELMED S**, Brkic V, Bidlingmaier M, Mercado MA, Van der Lely AJ, Biersasz N, Bolanowski M, Coculescu M, Schopohl J, Racz K, Glaser B, Goth M, Greenman Y, Trainer P, Mezosi E, Shimon I, Giustina A, Korbonits M, Bronstein M, Kleinberg D, Teichman S, Gliko-Kabir I, Mamluk R, Haviv A, Strasburger CJ: Safety and efficacy of oral octreotide in acromegaly: Results of a multicenter phase III trial. *J Clin Endocrinol Metab*, 100(4):1699-1708, 2015. PMID: 25664604
327. Zhou C, Jiao Y, Wang R Ren SG, Wawrowsky K, **MELMED S**: STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion. *J Clin Invest*, 125(4):1692-1702, 2015. PMID: 25774503 PMCID: PMC4396466
328. Liu N-A, Araki T, Cuevas-Ramos D, Hong J, Ben-Shlomo A, Tone Y, Tone M, **MELMED S**: Cyclin E-mediated human proopiomelanocortin regulation as a therapeutic target for Cushing Disease. *J Clin Endocrinol Metab*, 100(7):2557-2564, 2015. PMCID: PMC5393529
329. **MELMED S**: Fertility and Fragrance: Another cause of Kallmann Syndrome. *J Clin Invest*, 125:2275-8, 2015. PMID: 25985271 PMCID: PMC4497770
330. Herold K, Majzoub J, **MELMED S**, Pendergrass M, Schlumberger M: Endocrinology research-reflecting on the past decade and looking to the next. *Nat Rev Endocrinol*, 11:672-80, 2015.

331. **MELMED S:** New therapeutic agents for acromegaly. *Nat Rev Endo*, 12(2):90-8, 2016. PMID: 26610414
332. **MELMED S:** Pituitary Medicine: from discovery to patient-focused outcomes. *J Clin Endocrinol Metab*, 101(3):769-77, 2016. PMID: PMC4803158
333. Giustina A, Bevan JS, Bronstein MD, Casanueva FF, Chanson P, Petersenn S, Truong Thanh X-M, Sert C, Houchard A, Guillemin I, **MELMED S**. The Sagit Investigator Group. SAGIT: clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study. *Pituitary* 19(1):39-49, 2016. PMID: 26377024 PMID: PMC4710645
334. Greenman Y, Cooper O, Yaish I, Robenshtok E, Sagiv N, Jonash KT, Mallick J, Gertych A, Shimon I, Ram Z, **MELMED S**, Stern N. Treatment of clinically and non-functioning pituitary adenomas with dopamine agonists. *Eur J Endocrinol* 175(1):63-72, 2016. PMID: 27150495
335. Chesnokova V, Zonis, Zhou C, Recouvreux V, Ben Shlomo A, Araki T, Barrett R, Workman M, Wawrowky K, Ljubimov VA, Uhart M, **MELMED S:** Growth hormone is permissive for neoplastic colon growth. *Proc Natl Acad Sci USA* 113(23):E3250-9, 2016. PMID: PMC4988562
336. Christiansen JS, Backeljauw PF, Bidlingmaier M, Biller BMK, Boguszewski MCS, Casanueva FF, Chason P, Chatelain P, Choong CS, Clemmons DR, et al. Growth hormone research society perspective on the development of long-acting growth hormone preparations. *Eur J of Endocrinology* 174(6):C1-8, 2016.
337. Fleseriu M, Hashim I, Karavitaki N, **MELMED S**, Murad MH, Salvatori R, Samuels M. Hormonal replacement in hypopituitarism in Adults: An endocrine society clinical practice guideline. *J Clin Endocrinol Metab*, 101(11):3888-3921, 2016. PMID: 27736313
338. Araki T, Liu NA, Tone Y, Ben-Shlomo A, Heltsley R, Cuevas-Ramos D, Cooper O, Tone M, **MELMED S:** E2F1-mediated human POMC expression in ectopic Cushing's syndrome. *Endocrine-Related Cancer*, 23(11):857-870, 2016. PMID: 27935805 PMID: PMC5152695
339. Araki T, Liu X, Kameda H, Tone Y, H Fukuoka, M Tone, **MELMED S**. EGFR induces E2F1-mediated corticotroph tumorigenesis. *J Endo Society*, 1(2):127-143, 2017. PMID: 29264472 PMID: PMC5686559
340. Ben-Shlomo A, Liu NA, **MELMED S:** Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas. *Pituitary*. 20(1):93-99, 2017. PMID: 27900635
341. Cooper O, Bonert V, Moser F, Mirocha J, **MELMED S:** Altered pituitary gland structure and function in posttraumatic stress disorder. *J Endo Society*, 1(6): 577-587, 2017. PMID: 29264511 PMID: PMC5686623
342. Babu H, Ortega A, Nuno M, Dehghan A, Schweltzer A, Bonert VH, Carmichael JD, Cooper O, **MELMED S**, Mamelak AN. Long-term endocrine outcomes following endoscopic endonasal transsphenoidal surgery for acromegaly and associated prognostic factors. *Neurosurgery*, 81(2):357-366, 2017. PMID: 28368500
343. Recouvreux V, Wu B, Gao AC, Zonis S, Chesnokova V, Bhowmick N, Chung L, **MELMED S:** Androgen receptor regulation of local growth hormone in prostate cancer cells. *Endocrinology*, 158(7):2255-2268, 2017 PMID: PMC5505214
344. Casanueva FF, Barkan A, Buchfelder M, Klibanski A, Laws ER, Loeffler JS, **MELMED S**, Mortini P, Wass J, Giustina A. On behalf of the Pituitary Society, Expert Group on Pituitary Tumors. Criteria for the definition of Pituitary tumor centers of excellence (PTCOE): A Pituitary Society Statement. *Pituitary* 20:489-498, 2017. PMID: PMC5606938
345. **MELMED S**, Bronstein M, Chanson P, Klibanski A, Casanueva F, Wass J, Strasburger C, Luger A, Clemmons D, Giustina A. A consensus statement on acromegaly therapeutic outcomes. *Nat Rev Endocrinol*, 14(9):552-561, 2018. PMID: PMC7136157
346. Yamamoto M, Ben-Shlomo A, Kameda H, Fukuoka H, Deng N, Ding E, **MELMED S:** Somatostatin receptor subtype 5 modifies hypothalamic pituitary adrenal axis stress function. *J Clin Invest Insight* 3(19):e122932, 2018. PMID: PMC6237446

347. Gunther T, Schulz S, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castano JP, Wester HJ, Culler M, **MELMED S**, Schultz S: International union of basic and clinical pharmacology. X. Somatostatin receptors: Structure, function, ligands and new nomenclature. *Pharm Revs* 70(4): 763-835, 2018. PMID: 30232095 PMCID: PMC6148080
348. Labadzhyan A, Kim SM, Rhyu J, Araki T, Mahtabifard A, **MELMED S**. Thymic carcinoid with adrenocorticotrophic hormone-producing ectopic Cushing syndrome and empty sella. *AACE Clin Case Rep*. 2018 Sep-Oct;4(5):e375-e378. PMCID: PMC6939296
349. Kameda, H, Yamamoto M, Tone Y, Tone M, **MELMED S**: Proton sensitivity of corticotropin-releasing hormone receptor 1 signaling to proopiomelanocortin in male mice. *Endocrinology* 160(2):276-291, 2019. PMID: 30535142 PMCID: PMC6324021
350. Chesnokova V, Zonis S, Barrett R, Kameda H, Wawrowsky K, Ben-Shlomo A, Yamamoto M, Gleeson J, Bresee C, Gorbunova V, **MELMED S**: Excess growth hormone suppresses DNA damage repair in epithelial cells. *J Clin Invest Insight*. 7:4(3), pii:125762, 2019. PMID: 30728323 PMCID: PMC6413789
351. Chesnokova V, Zonis S, Barrett RJ, Gleeson JP, **MELMED S**. Growth hormone induces colon DNA damage independent of IGF-1. *Endocrinology*. 2019;160(6):1439-1447. PMCID: PMC6530523
352. Ho KY, Fleseriu M, Wass J, Van der Lely A, Barkan A, Giustina A, Casanueva FF, Heaney AP, Biermasz N, Strasburger C, **MELMED S**: A tale of pituitary adenomas: to NET or not to NET. Pituitary Society position statement. *Pituitary*, 22:569-573, 2019. PMID: 31571098
353. Chesnokova V, **MELMED S**: Growth hormone in the tumor microenvironment. *Archives of Endocrinology and Metabolism*. 63(6):568-75, 2019. PMID: 31939481 PMCID: PMC7025769
354. Giustina A, Bronstein MD, Chanson P, Petersenn S, Casanueva FF, Sert C, Houchard A, **MELMED S**. Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study. *Pituitary*. 22(5):476-487, 2019. PMID: 31338660 PMCID: PMC6728296
355. Bousquet C, Castano JP, Csaba Z, Culler M, Dournaud P, Epelbaum J, Feniuk W, Harmar A, Hills R, Hofland L, Hoyer D, Humphrey PPA, Kreienkamp J, Lupp A, **MELMED S**, Meyerhof W, O-Carroll AM, Patel YC, Reisine T, Reubi JC, Schindler M, Schmid H, Agnes Schonbrunn, Schulz S, Taylor JE, Tulipano G, Vezzani A, Hans-Jurgen Wester. Somatostatin receptors (version 2019.4) in the IUPHAR/BPS guide to pharmacology database. *IUPHAR/BPS Guide to Pharmacology CITE*, 2019:(4), 2019.
356. Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, Bolanowski M, Bonert V, Bronstein MD, Casanueva FF, Clemmons D, Colao A, Ferone D, Fleseriu M, Frara S, Gadelha MR, Ghigo E, Gurnell M, Heaney AP, Ho K, Ioachimescu A, Katznelson L, Kelestimir F, Kopchick J, Krssek M, Lamberts S, Losa M, Luger A, Maffei P, Marazuela M, Mazziotti G, Mercado M, Mortini P, Neggers, Pereira AM, Petersenn S, Puig-Domingo M, Salvatori R, Shimon I, Strasburger C, Tsagaraki S, Van der Lely AJ, Wass J, Zatelli MC, **MELMED S**. A consensus on the diagnosis and treatment of acromegaly comorbidities: An Update. *J Clin Endocrinol Metab*, 105(4):e937-e946, 2020. PMID: 31606735
357. Ho KKY, Fleseriu M, Wass J, van der Lely A, Barkan A, Giustina A, Casanueva FF, Heaney AP, Biermasz N, Strasburger C, **MELMED S**. The tale in evolution: clarity, consistency and consultation, not contradiction and confusion. *Pituitary*. 23(4):476-477, 2020. PMID: 31912348
358. Ben Shlomo A, Deng N, Ding E, Yamamoto M, Mamelak A, Chesnokova V, Labadzhyan A, **MELMED S**. DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas. *J Clin Invest*, 130 (11):5738-5755, 2020. PMID: 32673291 PMCID: PMC7598090
359. Bonert V, Mirocha J, Carmichael J, Yuen KCJ, Araki T, **MELMED S**. Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial. *J Clin Endocrinol Metab*, 105(9): e3236-3245, 2020. PMID: 32754748
360. Samson S, Nachtigall LB, Fleseriu M, Gordon M, Bolanowski M, Labadzhyan A, Ur E, Molitch M, Ludlam WH, Patou G, Haviv A, Biermasz NR, Giustina A, Trainer P, Strasburger CJ, Kennedy L,

- MELMED S.** Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. *J Clin Endocrinol Metab*, 105(10):1-13, 2020. PMID: 32882036 PMCID: PMC7470473
361. Gui Y, Thomas M, Garcia P, Karout M, Halder R, Michelucci A, Kollmus H, Zhou C, **MELMED S**, Schughart K, Balling R, Andre Mittelbronn MG, Nadeau J, Williams RW, Sauter T, Buttini M, Sinkkonen L. Pituitary Tumor Transforming Gene 1 orchestrates gene regulatory variation in mouse ventral midbrain during aging. *Frontiers Genetics*, 11:566734, 2020. PMCID: PMC7538689
362. Flaseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, Molitch ME, Samson SL, Strasburger CJ, van der Leley AJ, **MELMED S**: A pituitary society update to acromegaly management guidelines. *Pituitary*, 2020. PMID: 33079318
363. Kuo M, Maya MM, Bonert V, **MELMED S**: Prospective evaluation of incidental pituitary imaging findings in the sella turcica. *J Endo Society*, 5(2):bvaa186, 2020. PMCID: PMC7759030
364. Ho K, Flaseriu M, Kaiser U, Salvatori R, Brue T, Lopes B, Kunz P, Molitch M, Camper SA, Gadelha M, Syro LV, Laws E, Reincke M, Nishioka H, Grossman A, Barkan A, Casanueva F, Wass J, Mamelak A, Katznelson L, vander Lely AJ, Radovick S, Bidlingmaier M, Boguszewski M, Bollerslev J, Hoffman AR, Oyesiu N, Raverot G, Ben-Shomo A, Fowkes R, Shimon I, Fukuoka H, Pereira AM, Greenman Y, Heaney AP, Gurnell M, Johannsson G, Osamura RY, Buchfelder M, Zatelli MC, Korbonits M, Chanson P, Biermasz N, Clemmons DR, Karavitaki N, Bronstein MD, Trainer P, **MELMED S**. Pituitary neoplasm nomenclature workshop: Does adenoma stand the test of time? *J Endocrine Society*, 9;5(3): bvaa205, 2021. PMCID: PMC7874572
365. Cooper O, Bonert VS, Rudnick J, Pressman BD, Lo J, Salvatori R, Yuen KCJ, Flaseriu M, **MELMED S**: EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas. *J Clin Endocrinol Metab* 106(2):e917-e925, 2021. doi: 10.1210/clinem/dgaa805. PMID: 33150390; PMCID: PMC7823257.
366. Ben-Shlomo A, McLachlan S, Hwe J, Aliesky H, Hasselschwert D, Mirocha J, **MELMED S**: Insulin-Like Growth Factor 1 and Prolactin Levels in Chimpanzees (Pan troglodyte) Across the Lifespan. *J Endocrine Society*, 5(8):1-9, 2021.
367. Takako A, Tone Y, Yamamoto M, Kameda, Ben-Shlomo A, Yamada S, Takeshita A, Yamamoto M, Kawakami Y, Tone M, **MELMED S**: Two distinctive POMC promoters modify gene expression in Cushing Disease. *J Clin Endocrinol Metab*, 106(9):e3346-e3363, 2021. PMID: 34061962
368. Giustina A, Bronstein MD, Chanson P, Petersenn S, Casanueva FF, Sert C, Houchard A, **MELMED S**: International multicenter validation study of the SAGIT instrument in acromegaly. *J Clin Endocrinol Metab*, 106(12):3555-3568, 2021.
369. Flaseriu M, Dreval A, Bondar I, Vagapova G, Macut D, Pokramovich YG, Molitch ME, Leonova N, Raverot G, Grineva E, Poteshkin YE, Gilgun-Sherki Y, Ludlam WH, Patou G, Haviv A, Gordon MB, Biermasz NR, **MELMED S**, Strasburger CJ: A Phase 3, large international noninferiority trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands. *J Endo Society*, 5(1):A517, 2021. <https://doi.org/10.1210/jendso/bvab048.1056>
370. Chesnokova V, Zonis s, Apostolou A, Estrada HQ, Knott S, Wawrowsky K, Michelsen K, Ben-Shlomo A, Barrett R, Gorbunov V, Karalis K, **MELMED S**. Local non-pituitary growth hormone is induced with aging and facilitates epithelial damage. *Cell Rep* 37(11):110068, 2021 doi: 10.1016/j.celrep.2021.110068.
371. Flaseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, Boguszewski CL, Bronstein MD, Buchfelder M, Carmichael JD, Casanueva FF, Castinetti F, Chanson P, Findling J, Galdeha M, Geer EB, Giustina A, Grossman A, Gurnell, Ho K, Ioachimescu AG, Kaiser UB, Karavtiki N, Katznelson L, Kelly DF, Lacroix A, McCormack A, **MELMED S**, Molitch M, Mortini P, Newell-Price J, Nieman L, Pereira AM, Petersenn S, Pivanello R, Raff H, Reincke M, Salvatori R, Scaroni C, Shimon I, Strataki C, Swearinge B, Tabarin A, Yakahashi Y, Theodoropoulou M, Tsaganaki S, Alassi E, Varlamov EV, Vila G, Wass J, Webb SM, Zatelli M, Biller BK: Consensus on

- diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes Endocrinol 9:847-875, 2022.
372. Zhou C, Shen S, Moran R, Deng N, Marban E, **MELMED S**: Pituitary somatotroph adenoma-derived exosomes: characterization of nonhormonal actions. J Clin Endocrinol and Metab 107(2): 379-397, 2022 PMID: 34467411; DOI: 10.1210/clinem/dgab651
373. Flaseriu M, Dreval A, Bondar I, Vagapova G, Macut D, Pokramovich YG, Molitch ME, Leonova N, Raverot G, Grineva E, Poteshkin YE, Gilgun-Sherki Y, Ludlam WH, Patou G, Haviv A, Gordon MB, Biermasz NR, **MELMED S**, Strasburger CJ: Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomized controlled trial. The Lancet Diab and Endocrinol 10(2):102-111, 2022. DOI: 10.1016/S2213-8587(21)00296-5
374. Flaseriu M, Barkan A, Del Pilar MS, Darhi Y, De Pierrefeu A, Ribeiro-Oliverira Jr A, Peterssen S, Neggers S, **MELMED S**: Prevalence of comorbidities and concomitant medication use in acromegaly: Analysis of real-world data from the United States. Pituitary, 2022. DOI: 10.1016/S2213-8587(21)00296-5
375. Perramon M, Carvajal S, Reichenbach V, Guillermo F-V, Boix L, Macias L, Melgar-Lesmes P, Bruix J, **MELMED S**, Lamas S, Jimenez W: The pituitary tumor-transforming gene 1/delta like homolog 1 pathway plays a key role in liver fibrogenesis. Liver Intl 42(3):651-662, 2022.
376. Cooper O, Bonert V, Mamelak AN, Bannykh, **MELMED S**: Dural invasion as a marker of aggressive pituitary adenomas. Neurosurgery, 90(6):775-783, 2022 PMID: 35262532
377. Labadzhyan A, Wentzel K, Hamid O, Chow K, Kim S, Piro L, **MELMED S**. Endocrine autoantibodies determine immune checkpoint inhibitor-induced endocrinopathy: a prospective study. J Clin Endocrinol Metab, 107:1976-1982, 2022. PMID: 35303106
378. Boguszewski MCS, Boguszewski CL, Chemaitilly W, Cohen LE, Gebauer J, Higham C, Hoffman AR, Polak M, Yuen KCJ, Alos N, Antal Z, Bidlingmaier M, Biller BMK, Brabant G, Choong CSY, Cianfarani S, Clayton PE, Coutant R, Cardoso-Demartini AA, Fernandez A, Grimberg A, Gudmundsson K, Guevara-Aquirre J, Ho KKY, Horikawa R, Isidori AM, Jorgensen JOL, Kamenicky P, Karavitaki N, Kopchick JJ, Lodish M, Luo XP, McCormack AI, Meacham L, **MELMED S**, Sogol Mostoufi-Moab S, Müller HL, Neggers SJCMM, Aguiar-Oliveira MH, Ozono K, Pennisi PA, Popovic V, Radovick S, Savendahl L, Touraine P, van Santen HM, Johannsson G. Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours – A consensus statement. Eur J Endocrinol, 186(6): 35-52, 2022. PMID: 35319491
379. Samson SL, Nachtigall LB, Flaseriu M, Jensterle M, Manning PJ, Elenkova A, Molitch ME, Ludlan WH, Patou G, Haviv A, Biermasz NR, Giustina A, Strasburger CJ, Kennedy L, **MELMED S**: Durable Biochemical Response and Safety with Oral Octreotide Capsules in Acromegaly. Eur J Endocrinology, 187(6): 733-741, 2022. PMID: 36173649
380. Liu NA, Ben-Shlomo A, Carmichael JD, Wang C, Swerdloff RS, Heaney AP, Barkhoudarian G, Kelly D, Nouredin M, Lu L, Desai M, Stolyarov Y, Yuen K, Mamelak AN, Mirocha J, Tighiouart M, **MELMED S**. Treatment of Cushing disease with pituitary-targeting seliciclib. J Clin Endocrinol Metab, 15;108(3):726-735, 2022. PMID: 36214832
381. Even-Zohar N, Metin-Armagan D, Ben-Shlomo A, Sareen D, **MELMED S**. Generation of isogenic and homozygous MEN1 mutant cell lines from patient-derived iPSCs using CRISPR/Cas9. Stem Cell Res, 69:103124, 2023. PMID: 37209468
382. Petersenn S, Flaseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BB, Bronstein M, Chanson P, Fukuoka H, Gadelha M, Greenman Y, Gurnell M, Ho KKY, Honegger J, Ioachimescu A, Kaiser UB, Karavitaki N, Katznelson L, Lodish M, Maiter D, Marcus HJ, McCormack A, Molitch M, Muir CA, Neggers S, Pereira AM, Pivonello R, Post K, Raverot G, Salvatori R, Samson S, Shimon I, Spencer-Segal J, Vila G, Wass J, **MELMED S**. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international consensus statement. Nat Rev Endocrinol 2023 (accepted).

383. Flaseriu M, Barkan A, Brue T, Duquesne E, Houchard A, del Pilar Schneider M, Ribeiro-Oliveira Jr A, **MELMED S**. Treatment patterns, adherence, persistence, and healthcare resource utilization in acromegaly: a real-world analysis. J Endocr Soc, 2023. DOI: 10.1210/jendso/bvad104
384. Ho KKY, Kaiser UB, Chanson P, Gadelha M, Wass J, Nieman L, Little A, Aghi MK, Raetzman L, Post K, Raverot G, Borowsky AD, Erickson D, Castaño JP, Laws ER, Zatelli MC, Sisco J, Esserman L, Yuen KCJ, Reincke M, **MELMED S**. Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification. Nat Rev Endocrinol, 2023. DOI: 10.1038/s41574-023-00883-8. PMID: 37592077.
385. Jens Otto L Jørgensen, Wouter W de Herder, Wendy A Martin, Teodora Kolarova, Muriël Marks, Cecilia Follin, Wanda Geilvoet, **MELMED S**. Key Device Attributes for Injectable Somatostatin Receptor Ligand Therapy in Acromegaly and Neuroendocrine Tumours. DOI: 10.1007/s12325-023-02627-6. PMID: 37573277.
386. Ho KKY, Flaseriu M, Wass J, Katznelson L, Raverot G, Little AS, Castaño JP, Reincke M, Lopes MB, Kaiser UB, Chanson P, Gadelha M, **MELMED S**. A comprehensive clinical classification for pituitary neoplasms to guide therapy and prognosis: a proposal. Lancet Diabetes Endocrinol 2023 (in revision).
387. Bonert V, Gomez D, Zonis S, Zhang Y, Ramanujan VK, Kim S, Mamelak AN, **MELMED S**. Predictors of postoperative biochemical control in acromegaly: a real-world prospective study. J Clin Endocrinol Metab 2023 (submitted).
388. Chesnokova V, Zonis S, Apaydin T, Barrett R, **MELMED S**. Non-pituitary growth hormone enables colon cell senescence evasion. Aging Cell 2023 (in revision)

REVIEWS-PEER REVIEWED

1. Morley JE, **MELMED S**: Gonadal dysfunction in systemic disorders. Metabolism 28:1051, 1979.
2. **MELMED S**, Braunstein GD, Horvath E, Ezrin C, Kovacs K: Pathophysiology of acromegaly. Endocrine Reviews 4:271-290, 1983.
3. **MELMED S**, Chang J, Braunstein GD, Becker D: Growth hormone and prolactin-secreting pituitary tumors. Ann Intern Med 105:238-253, 1986.
4. **MELMED S**, Fagin JA: Acromegaly update: Etiology, Diagnosis and Management. West J Med 146:328-336, 1987.
5. **MELMED S**: Acromegaly. New Eng J Med 322:966-977, 1990.
6. Greenman Y, **MELMED S**: Diagnosis and management of nonfunctioning pituitary tumors. Ann Rev of Med, Vol. 47:95-106, 1996.
7. **MELMED S**, Ho K, Thorner M, Klibanski A, Reichlin S: Recent advances in pathogenesis, diagnosis and management of acromegaly. J Clin Endocrinol Metab, 80:3395-3402, 1995.
8. Shimon S, **MELMED S**: Genetic basis of endocrine disease: Pituitary tumor pathogenesis. J Clin Endocrinol Metab, 82:1675-1681, 1997.
9. **MELMED S**: gp130-related cytokines and their receptors in the pituitary. Trends in Endocrinol and Metab 8(10):391-397, 1998.
10. Ray DW, Ren S-G, **MELMED S**: Leukemia inhibitory factor regulates proopiomelanocortin transcription. Proc New York Acad of Sci, 17:189-202, 1997.
11. Ray D, **MELMED S**: Pituitary cytokine and growth factor expression and action. Endocrine Reviews 18:206-228, 1997.
12. Auernhammer C, **MELMED S**: Leukemia inhibitory factor-neuroimmune modulator of endocrine function. Endocrine Reviews, 21:313-345, 2000.
13. Heaney A, **MELMED S**: New Pituitary Oncogenes. Endocrine Related Cancer, 7:3-15, 2000.
14. Chesnokova V, **MELMED S**: Neuro-immuno-neuroendocrine modulation of the HPA axis by gp130 signaling molecules. Endocrinology, 143:1571-1574, 2002.

15. **MELMED S**: Mechanisms for pituitary tumorigenesis: the plastic pituitary. *J Clin Invest* 112 (11):1603-1618, 2003.
16. Turner HE, Harris AL, **MELMED S**, Wass JA: Angiogenesis in endocrine tumours. *Endocrine Reviews*, 24:600-632, 2003.
17. Ben-Shlomo A, **MELMED S**: The role of pharmacotherapy in peri-operative management of patients with acromegaly. *J Clin Endocrinol Metab*, 88:963-8, 2003.
18. Heaney A, **MELMED S**: Molecular targets in pituitary tumors. *Nature Rev Cancer*, 4:285-295, 2004.
19. **MELMED S**, Acromegaly. *New Engl J Med*, 355:2558-2573, 2006.
20. Vlotides G, Eigler T, **MELMED S**: Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. *Endo Rev*, 28:165-186, 2007.
21. **MELMED S**: Acromegaly pathogenesis and treatment. *J Clin Investigation*, 119:3189-202, 2009. PMID: PMC2769196
22. Ben-Shlomo A, **MELMED S**: Pituitary somatostatin receptor signaling. *Trends in Endocrinol and Metab*, 21:123-133, 2010. PMID: PMC2834886
23. Ljubimov V, Vlotides G, Zhou C, Yu R, **MELMED S**: Pttg1. *UCSD-Nature Mol Pages*, 2011.
24. Cooper O, Vlotides G, Fukuoka H, Greene MI, **MELMED S**: Expression and function of pituitary ErbB receptors and ligands. *Endocr Related Cancer*, 18:R197-R211, 2011.
25. Colao A, Grasso LFS, Giustina A, **MELMED S**, Chanson P, Pereira AM, Pivonello R. Acromegaly. *Nat Rev Dis Primers*. 2019 Mar 21;5(20): 1-17.
26. **MELMED S**: Pathogenesis and Diagnosis of Growth Hormone Deficiency in Adults. *N Engl J Medicine*, 380 (26): 2551-2562, 2019.
27. Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Boguszewski C, Bolanowski M, Bollerslev J, Bonert V, Bronstein MD, Buchfelder M, Casanueva F, Chanson P, Clemmons D, Fleseriu M, Formenti AM, Freda P, Gadelha M, Geer E, Gurnell M, Heaney AP, Ho KKY, Ioachimescu AG, Lamberts S, Laws E, Losa M, Maffei P, Mamelak A, Mercado M, Molitch M, Mortini P, Pereira AM, Petersenn S, Post K, Puig-Domingo M, Salvatori R, Samson SL, Shimon I, Strasburger C, Swearingen B, Trainer P, Vance ML, Wass J, Wierman ME, Yuen KCJ, Zatelli MC, **MELMED S**. Multidisciplinary management of acromegaly: a consensus. *Rev Endocrinol Metab Dis*, 21(4):667-678, 2020.
28. **MELMED S**: Pituitary Tumor Endocrinopathies, *N Engl J Med*, 382:937-50, 2020.
29. Chesnokova V, **MELMED S**. Peptide hormone regulation of DNA damage responses. *Endocr Rev*. 41:519-537, 2020. PMID: 32270196
30. Alexander SP, Christopoulos A, Davenport AP, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Southan C, Davies JA, Abbracchio MP, Alexander W, Al-Hosaini K, Bäck M, Barnes NM, Bathgate R, Beaulieu JM, Bernstein KE, Bettler B, Birdsall NJM, Blaho V, Boulay F, Bousquet C, Bräuner-Osborne H, Burnstock G, Caló G, Castaño JP, Catt KJ, Ceruti S, Chazot P, Chiang N, Chini B, Chun J, Cianciulli A, Civelli O, Clapp LH, Couture R, Csaba Z, Dahlgren C, Dent G, Singh KD, Douglas SD, Dournaud P, Eguchi S, Escher E, Filardo EJ, Fong T, Fumagalli M, Gainetdinov RR, Gasparo M, Gerard C, Gershengorn M, Gobeil F, Goodfriend TL, Goudet C, Gregory KJ, Gundlach AL, Hamann J, Hanson J, Hauger RL, Hay DL, Heinemann A, Hollenberg MD, Holliday ND, Horiuchi M, Hoyer D, Hunyady L, Husain A, IJzerman AP, Inagami T, Jacobson KA, Jensen RT, Jockers R, Jonnalagadda D, Karnik S, Kaupmann K, Kemp J, Kennedy C, Kihara Y, Kitazawa T, Koziellewicz P, Kreienkamp HJ, Kukkonen JP, Langenhan T, Leach K, Lecca D, Lee JD, Leeman SE, Leprince J, Li XX, Williams TL, Lolait SJ, Lupp A, Macrae R, Maguire J, Mazella J, McArdle CA, **MELMED S**, Michel MC, Miller LJ, Mitolo V, Mouillac B, Müller CE, Murphy P, Nahon JL, Ngo T, Norel X, Nyimanu D, O'Carroll AM, Offermanns S, Panaro MA, Parmentier M, Pertwee RG, Pin JP, Prossnitz ER, Quinn M, Ramachandran R, Ray M, Reinscheid RK, Rondard P, Rovati GE, Ruzza C, Sanger GJ, Schöneberg T, Schulte G, Schulz S, Segaloff DL, Serhan CN, Stoddart LA, Sugimoto Y, Summers R, Tan VP, Thal D, Thomas WW, Timmermans PBMWM, Tirupula K, Tulipano G, Unal H, Unger T, Valant C, Vanderheyden P, Vaudry D, Vaudry H,

Vilardaga JP, Walker CS, Wang JM, Ward DT, Wester HJ, Willars GB, Woodruff TM, Yao C, Ye RD: The concise guide to pharmacology 2021/22: G protein-coupled receptors. Br J Pharmacol, 178 Suppl 1: S27-S156, 2021.

31. Chesnokova V, **MELMED S**: GH and senescence: a new understanding of adult GH action. J Endocrine Soc 6(1):bvab177, 2022. DOI: 10.1016/S2213-8587(21)00296-5. PMID: 34909519
32. **MELMED S**, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, Reincke M, Johannsson G, Beckers A, Fleseriu M, Giustina A, Wass JAH, Ho KKY: Clinical biology of the pituitary adenoma. Endocr Rev, 43(6):1003-1037, 2022. PMID: 35395078
33. Fleseriu M, Langlois F, Lim DST, Varlamov E, **MELMED S**: Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol, 10(11):804-826, 2022. PMID: 36209758
34. Labadzhyan A, **MELMED S**. Molecular targets in acromegaly. Front Endocrinol (Lausanne), 13:1068061, 2022. PMID: 36545335
35. Chesnokova V, **MELMED S**. Non-pituitary GH regulation of the tissue microenvironment. Endocr Relat Cancer, 30(7):e230028, 2023. PMID: 37066857
36. Fleseriu M, Varlamov EV, Hinojosa-Amaya JM, Langlois F, **MELMED S**. An individualized approach to the management of Cushing disease. Nat Rev Endocrinol, 2023. DOI: 10.1038/s41574-023-00868-7. PMID: 37537306

EDITORIALS

1. **MELMED S**, Braunstein GD: Bromocriptine and pleuropulmonary disease. Arch Int Med 149:258, 1989.
2. Herman V, **MELMED S**: Clonality of endocrine tumors. Endocrine Pathology 2:61-63, 1991.
3. Prager D and **MELMED S**: Insulin and insulin-like growth factor I receptors: Are there functional distinctions? Endocrinology 132:1419-1420, 1993.
4. Drange M, **MELMED S**: To sleep perchance to eat. J Clin Endo Metab, 82:1311-1312, 1997.
5. **MELMED S**: Fond Farewell. Endocrinology 139:821, 1998.
6. **MELMED S**: Tight control of growth hormone: an attainable outcome for acromegaly treatment. J Clin Endocrinol Metab (Editorial), 83:3409-3410, 1998.
7. **MELMED S**: The immuno-neuroendocrine interface. J Clin Invest, 108:1563-1566, 2001.
8. **MELMED S**: Supplemental growth hormone in healthy adults: the endocrinologist's responsibility (Editorial). Nat Clin Pract Endocrinol Metab 2:1, 2006.
9. **MELMED S**: Melvin M. Grumbach 1925-2016. Proc Natl Acad Sci 114: 4845-4847, 2017.
10. Ho KKY, Gadelha M, Kaiser UB, Reincke M, **MELMED S**: The NETting of pituitary adenoma: a gland illusion. Pituitary, 25(3): 349-351, 2022
11. **MELMED S**: Is GH Replacement for Adult GH Deficiency Safe? J Clin Endocrinol Metab, 107(10): e4238-e4239, 2022.
12. **MELMED, S**. A fond farewell. Pituitary (2024). <https://doi.org/10.1007/s11102-023-01380-x>

LETTERS TO THE EDITOR

1. **MELMED S**: Radiotherapy for Acromegaly. N Eng J Med 323:612-613, 1990 (letter).
2. **MELMED S**, Ezzat S: Colonic Polyps in Acromegaly (letter). Ann Int Med 115:232-233, 1991.
3. **MELMED S**: Letter from the United States. The Endocrinologist 48:13, 1998.
4. Giustina A, **MELMED S**: Acromegaly Consensus: The next steps. J Clin Endocrinol Metab 88:1913-1914, 2003.
5. **MELMED S**: Acromegaly. N Engl J of Med, 356:1274-1276, 2007.
6. Fleseriu M, Castinetti, Gadelha M, Giustina A, Lacroix A, **MELMED S**, Newell-Price J, Pivonello R, Reincke M, Biller BMK. Osilodrostat for the treatment of Cushing's disease: efficacy, stability and persistence. Lancet Diabetes Endocrinol, 10:384-387, 2022.

TEXTBOOKS

1. Robbins R and **MELMED S** (eds): Acromegaly: A century of scientific and clinical progress, Plenum Press, NY, 1987.
2. Draznin B, **MELMED S**, Le Roith D: Molecular & Cellular Biology of Diabetes Mellitus, A. Liss, N.Y., 1988: Vol I - Insulin Secretion Vol II - Insulin Action Vol III - Complications
3. **MELMED S** and Robbins R: Current issues in Endocrinology and Metabolism: Molecular and Clinical Advances in Pituitary Disorders, Blackwell Scientific Publications, Boston, 1991.
4. **MELMED S**: Acromegaly. Endo & Metab Clinics of No. America (Guest Editor), WB Saunders, Vol. 21:3, 1992.
5. **MELMED S** (ed): Molecular and Clinical Advances in Pituitary Disorders: the Proceedings of the 3rd International Pituitary Congress, Marina Del Rey, CA, 1993.
6. **MELMED S**: The Pituitary. Blackwell, Boston, 1995; 2000 2nd Edition.
7. **MELMED S**: Oncogenesis and Molecular Biology of Pituitary Tumors, Karger Publications, Switzerland, 1996.
8. Conn P.M. and **MELMED S** (eds): Endocrinology: Basic and Clinical Principles, Humana Press, Inc., Totowa NJ, 1997.
9. **MELMED S**: Hormone Action: Basic and Clinical Aspects, Biomedica 2000.
10. Baxter J, New M and **MELMED S** (eds): Genetics in Endocrinology by Lippincott-Raven Publishers, 2001.
11. Burger HG, Loriaux DL, Marshall JC, **MELMED S**, Odell WD, Potts W, Rubenstein AH: 4th Edition, Endocrinology. Vols I, II, and III DeGroot LJ, Jameson JL (Eds), WB Saunders, PA 2001; 5th Edition, 2005.
12. **MELMED S** and Conn PM (Eds): 2nd Edition, Endocrinology: Basic and Clinical Principles, Humana Press, 2005.
13. Kronenberg H, Larsen R, **MELMED S**, Polonsky K (eds): Williams Textbook of Endocrinology (Saunders), 10th Edition, 2002; 11th Edition 2006.
14. DeGroot LJ and Jameson JL, Kretser DD, Grossman AB, Marshall JC, **MELMED S**, Potts JT Jr, Weir GC (eds): Endocrinology 5th Edition, Elsevier Publishers, 2006.
15. **MELMED S**, Rochefort H, Chanson P, Christen Y (Eds): Research and Perspectives in Endocrine Interactions: Hormonal Control of Cell Cycle, Springer-Verlag 2006.
16. Kronenberg HM, **MELMED S**, Polonsky KS, Larsen PR (Eds): Williams Textbook of Endocrinology, 11th Edition, Elsevier, 2008.
17. DeGroot LJ and Jameson JL, Kretser DD, Grossman AB, Marshall JC, **MELMED S**, Potts JT Jr, Weir GC (eds): Endocrinology 6th Edition, Elsevier Publishers, 2010.
18. **MELMED S**, Polonsky KS, Larsen PR, Kronenberg HM (Eds): Williams Textbook of Endocrinology, 12th Edition, Elsevier, 2011.
19. **MELMED S**: Encyclopedia of Human Biology (3rd Edition), Elsevier; Editor (Endocrine), 2013.
20. DeGroot LJ and Jameson JL, Kretser DD, Grossman AB, Marshall JC, **MELMED S**, Potts JT Jr, Weir GC (eds): Endocrinology 7th Edition, Elsevier Publishers, 2015.
21. **MELMED S**, Polonsky KS, Larsen PR, Kronenberg HM (Eds): Williams Textbook of Endocrinology, 13th Edition, Elsevier Publications, 2016.
22. **MELMED S**: The Pituitary. Elsevier Academic Press, 3rd Edition, 2011 and 4th Edition 2017.
23. **MELMED S**, Auchus RJ, Goldfine AB, Koenig RJ, Rosen CJ (Eds): Williams Textbook of Endocrinology, 14th Edition, Elsevier Publications, 2020.
24. **MELMED S**: The Pituitary, 5th Edition (S Melmed, Editor). Elsevier Publications, 2022.

NON-PEER REVIEWED

1. **MELMED S**: Acromegaly update. 38th Annual Endocrine Society Postgraduate Assembly, Los Angeles, 1986 (presented).
2. **MELMED S**: Pituitary Tumors: Medical Management. Advances in Neuroophthalmology 18th Jules Stein Eye Institute Postgraduate Seminar, p 41, 1987.
3. **MELMED S**: Medical Management of Pituitary Tumors. 39th Annual Endocrine Society Postgraduate Assembly, San Francisco 1987.
4. **MELMED S**: Medical Management of Pituitary Tumors. Audio-Digest 25:20, 1987.
5. **MELMED S**: Use of Somatostatin in the Management of Pituitary and Extrapituitary Acromegaly. Peptidomimetic Therapy: A novel approach to Endocrine and Gastrointestinal Diseases, San Francisco, 1988 (presented).
6. **MELMED S**: Use of somatostatin in acromegaly. Peptidomimetic Therapy, Baylor University, Houston, 1988 (presented).
7. **MELMED S**: Peptide Therapy for Pituitary Tumors. Peptide Therapy. 1(4): 10-11, 1989.
8. **MELMED S**: Management of growth hormone hypersecretion. Endocrine Society 42nd Postgraduate Assembly, 1990.
9. **MELMED S**: Evidence for an intrinsic cell mutation in pituitary tumorigenesis: Techniques, Results and Perspectives. 4th Meeting of the International Pituitary Pathology Club, Vaison La Romaine, France, 1990.
10. **MELMED S**: Physician's Dilemma: The management of patients with pituitary tumors and acromegaly. Preliminary results of a multi-center trial with octreotide acetate: Clinical activity. The Endocrine Society Meeting, Washington, DC, 1991.
11. Ezzat S, **MELMED S**: Are patients with acromegaly at increased risk for neoplasia? *J Clin Endocrinol and Metab* 72:245-249, 1991.
12. Sassolas G, **MELMED S**: Symposium: Basic sandostatin research. *Metab Clin and Exp* 41:11-16, 1992.
13. **MELMED S**: Recent advances in Somatostatin Basic Research: Action of somatostatin on the GH/IGF-I axis: new advances. Satellite Symposium, Sandostatin, State-of-the-art, Monte Carlo, 1991 (presented).
14. **MELMED S**: Pathophysiology of acromegaly. 10th Spanish Endocrine Congress Meeting, Santiago de Compostela, Spain, 1991 (presented).
15. **MELMED S**. Acromegaly: Therapeutic Options in Endocrine Society Postgraduate Assembly Mtg, 1993.
16. Prager D, Yamasaki H, **MELMED S**: Pituitary IGF-I receptor structure function in Proceedings of 3rd International Pituitary Congress pp. 127-134, 1993.
17. Pei L, Prager D, Scheihauer B, **MELMED S**, Herman V. Molecular characterization of pituitary tumors in Proceedings of 3rd International Pituitary Congress pp. 21-28, 1993.
18. **MELMED S**, Treatment of Acromegaly in Lifetime Medical Television by Alpha Telecommunications (video), May-July 1993.
19. **MELMED S**. Pathophysiology of acromegaly: a review of the current state of knowledge in Acromegaly: Therapeutic Strategies by Excerpta Medica, 1993.
20. **MELMED S**. Comprehensive Management of Acromegaly. *Metabolism*, Vol 43 pp. 1-5, 1994.
21. **MELMED S**: Acromegaly: Modern Diagnosis and Therapy. Postgraduate course in Clinical Endocrinology, Massachusetts General Hospital-Harvard Medical School, 1995.
22. **MELMED S**: Unwanted effects of growth hormone excess in the adult. Growth Symposium, Santiago de Compostela, 1995
23. **MELMED S**: Structure and function of the dopamine receptor. *Endocrinologist* 7:385-389, 1997.
24. **MELMED S**: Molecular pathophysiology of acromegaly. *Acta Pediatr Scan* 417:45-48, 1996
25. **MELMED S**: Acromegaly in Somatostatin Analogs: Basic and clinical perspectives, Sorrento, Italy 1995.

26. **MELMED S:** Treatment of Acromegaly. UpToDate in Medicine, Vol. 5, 1996-2020
27. **MELMED S:** Clinical manifestations of Acromegaly. UpToDate in Medicine, Vol. 5, 1996-2020
28. **MELMED S:** Diagnosis of Acromegaly. UpToDate in Medicine, Vol. 5, 1996-2020
29. **MELMED S:** Physiology of growth hormone. UpToDate in Medicine, Vol 5, 1996-2020
30. Prezant TR, **MELMED S:** Molecular pathogenesis of pituitary tumors in Current Opinion in Endocrinology and Diabetes. 9:61-78 2002.**MELMED S:** Pharmacotherapy of Acromegaly. Clinical Endocrinology Update, Syllabus 109-114, 1999.
31. Klibanski A, Ho K, Freda PU, Clemmons DR, Barkan AL, Kleinberg DL, Trainer PJ, Swearingen B, Molitch ME, Wass JAH, Thorner MO, **MELMED S**, Strasburger CJ, Frohman LA. State-of-the-art strategies for the diagnosis and management of acromegaly. The Endocrinologist 2001 11:223-232.
32. **MELMED S:** Is it time for new indications for GH? Endocrine Today, Clinical news on diabetes and endocrine disorders article, 2007.
33. Chesnokova V, **MELMED S:** Pituitary senescence: The evolving role of Pttg. Mol Cell Endocrinol, 326:55-59, 2010. PMID: PMC2906651
34. **MELMED S:** Challenges in life sciences and health systems in 21st Century. RECOOP HST Association Mtg in Croatia, 2014
35. **MELMED S:** Uncommon knowledge: Advancing medical therapy of pituitary tumors. Basic Researcher Perspective. Endocrine News Magazine, October 2014, pp 50-55.
36. **MELMED S:** Letter from America Endocrinology: “Sine Stercore Tauri”. The Endocrinologist Issue 114/15 p. 17, 2014.
37. **MELMED S:** Pituitary Tumors. Endocrinol Metab North Am. 44(1):1-9, 2014.
38. **MELMED S**, Kleinberg DL, Bonert V, Fleseriu M: Acromegaly: Assessing the disorder and navigating therapeutic options for treatment. Endocrine Practice, 20(1):7-17, 2014.
39. Pathak A, **MELMED S**. Health Outcomes in Acromegaly: Comorbidity and Cancer Surveillance Beyond IGF-1. In: ENDO 2019 Meet-the-Professor Clinical Case Management. 2019 ed. DC: Endocrine Society; 2019:147-150.

BOOK CHAPTERS

1. **MELMED S**, Nelson M. Kaplowitz N, Yamada T, Hershman JM: Role of intracellular glutathione in modulation of thyroxine conversion to triiodothyronine and hormone production by cultured pituitary cells. In: Thyroid Research, Stockigt JR, Nagataki S (Eds), Australian Academy of Science, Canberra, p 453, 1980.
2. **MELMED S**, Hershman JM: The Thyroid and Aging. pp 33-54. In: Endocrine Aspects of Aging, Korenman S. (Ed.), Elsevier, Science Publishing Co., New York, 1982.
3. **MELMED S:** Control of prolactin synthesis and secretion in Seminars in Reproductive Endocrinology, 2:1-8, 1984.
4. Davidson MB, **MELMED S:** Insulin binding and action in rats bearing growth hormone secreting transplantable tumors. In: Lessons from Animal Diabetes, Ed. by Shafir E, Renold AE, p 231, London: John Libbey, 1984.
5. **MELMED S:** Human growth hormone gene regulation in somatotroph tumors. Acromegaly Centennial; Plenum Press, NY, 1987.
6. **MELMED S**, Braunstein GD: Endocrine dysfunction in amyotrophic lateral sclerosis. Neurologic Clinics Feb 1987 pp 33-42.
7. **MELMED S:** Ectopic Pituitary and Hypothalamic Hormone Syndromes. Endocrinology & Metabolism Clinics of North America; W.B. Saunders Company, Sept 1987.
8. **MELMED S:** Feedback regulation of growth hormone secretion in the Brain as an Endocrine Organ eds Cohen M, Foa P: Springer Verlag, NY 1988.

9. **MELMED S:** Growth factor regulation of pituitary function. in Neuroendocrine Perspectives eds. E.E. Muller and R.M. Macleod, Springer Verlag NY, 1988.
10. **MELMED S:** Oncogenes and the Thyroid in Thyroid Today (ed) J. Oppenheimer, Vol 11, January 1988.
11. Fagin J, Morita S, **MELMED S:** Cellular Pathophysiology of prolactinomas in Prolactin-related Disorders. RE Blackwell and RJ Chang (eds), MacMillan, NJ, 1987.
12. Prager D, **MELMED S:** Insulin regulation of Growth Hormone Gene Expression in Draznin B, Melmed S, LeRoith D, (eds) Molecular & cellular biology of diabetes mellitus, A. Liss NY, 1988 pp 163-173.
13. **MELMED S,** Morita S: Triiodothyronine regulation of GH secretion: additive effects of retinoic acid. Proceedings Nagasaki, International Symposium on Graves Disease ed S. Nagasaki.
14. **MELMED S,** Braunstein GD: Diseases of hypothalamus and pituitary in Stein's Textbook of Internal Medicine, 3rd Edition, Little Brown, 9:2141-2155, 1989.
15. Festoff BW, **MELMED S,** Smith R: Therapeutic trial of recombinant human growth hormone in amyotrophic lateral sclerosis, Advances in Neuromuscular Diseases p 117-126, 1989.
16. **MELMED S,** Prager D, Fagin J: Feedback regulation of growth hormone gene expression by insulin-like growth factor I. Molecular and Cellular Biology of Insulin-like Growth Factors and their Receptors by D. LeRoith and M. K. Raizada (eds) Plenum Publishing Co., pp. 57-72, 1988.
17. Smith RA, Jacoby S, Festoff B, Peterson L, **MELMED S,** Molnar G, Sherman B, and Frane J: The Influence of compliance and other human factors on ALS treatment trials. In: Progress in Clinical Trials. Amyotrophic Lateral Sclerosis. F.C. Rose, Ed., Demos Publications, New York, 1990, pp 1-14.
18. **MELMED S:** Hereditary endocrine tumors in Current Therapy in Endocrinology and Metabolism. Ed. W. Bardin, Mosby, NY pp. 496-498, 1990.
19. Ezzat S, **MELMED S:** Pituitary Tumors in the Elderly by J Morley, S Korenman (eds), Blackwell Scientific Publications. Geriatric Endocrinol, pp. 58-69, 1990.
20. **MELMED S,** Prager D: Molecular Biology of the Endocrine System K. Kovacs & S. Asa (eds) Endocrine Pathology, Blackwell Scientific Publications, NY, Vol 1 pp. 124-142, 1991.
21. **MELMED S:** Acromegaly. Rakel, Conn's Current Therapy, Pub: W.B. Saunders Company, pp. 565-568, 1991.
22. Herman V, Fagin J, Gonsky R, Namba H, Weiss M, Becker D, **MELMED S:** Clonal origin of human pituitary tumors and evidence for transforming activity in Molecular and Clinical Advances in Pituitary Disorders, Blackwell Scientific, pp 247-252, 1991.
23. **MELMED S:** Extra-pituitary Acromegaly. Ed. W. Daughaday, Endocrinology and Metabolism Clinics of North America, pp. 507-518, 1991.
24. **MELMED S,** Herman VS, Prager D, Yamasaki H, Gonsky R, Fagin J: Pituitary adenomas: New trends in basic and clinical research: Role of growth factors in regulation of pituitary hormone production and in the pathogenesis of pituitary tumors. Elsevier Science Publishing Co., pp. 123-130, 1991.
25. **MELMED S:** Etiology of pituitary acromegaly. Endo & Metab Clinics of No. America, WB Saunders, pp. 539-551, 1992.
26. **MELMED S:** Pathogenesis of pituitary tumors in Molecular Genetics of Nervous Tumors by A. Levine and H. Schmidek (eds), pp. 255-263, 1993.
27. **MELMED S:** Acromegaly in Endocrine Tumors by E. Mazzaferri and N. Samaan (eds) published by Blackwell Scientific Publications, 1993.
28. Prager D, **MELMED S:** Somatotroph IGF-I signalling in Role of IGF-I in the nervous system. D. LeRoith (ed) NY Academy of Sciences, 1993.
29. **MELMED S.** Hereditary endocrine tumors in Current Therapy in Endocrinology and Metabolism, Mosby, 1993, Philadelphia.
30. **MELMED S.** General aspects of the management of pituitary tumors by surgery or radiation therapy in DeGroot's Textbook of Endocrinology, WB Saunders Company, Philadelphia, 1993.
31. **MELMED S.** Tumor mass effects of lesions in the hypothalamus and pituitary in DeGroot's Textbook of Endocrinology, WB Saunders Company, Philadelphia, 1993.

32. **MELMED S.** Molecular mechanisms of tumor formation in hereditary and sporadic tumors of the men I type: pituitary neoplasia in Endocrinology and Metabolism Clinics of North America, R. Gagel (ed), 1993.
33. **MELMED S.** Braunstein GD: Disorders of the hypothalamus and anterior pituitary in Stein's Textbook of Internal Medicine, 4th Edition, Little Brown, J.H. Stein (ed), pp 1773-1788, 1993.
34. **MELMED S.** Molecular mechanisms of pituitary tumorigenesis in The Pituitary, H. Imura (ed), Raven Press, 1994.
35. **MELMED S.** Octreotide stimulates insulin-like growth factor (IGF) binding protein-1: A novel mechanism of drug action in acromegaly in Seminars in Oncology, L. Kvolz, T. O'Dorisio (eds), WB Saunders Company, 1994.
36. Prager D, **MELMED S.** Mechanisms for insulin-like growth factor I regulation of growth hormone secretion. B B Bercu and R F Walker (eds) Growth Hormone II: Basic and Clinical Aspects, pp. 73-84, 1994.
37. Asa SL, Kovacs K, **MELMED S:** The hypothalamic-pituitary axis. S. Melmed (ed.) in The Pituitary by Blackwell Scientific, 1994.
38. Herman-Bonert VS, Prager D, **MELMED S:** Growth Hormone. S. Melmed (ed.) in The Pituitary by Blackwell Science, 1994.
39. **MELMED S:** Acromegaly. S. Melmed (ed.) in The Pituitary by Blackwell Science, 1994.
40. Greenman Y, **MELMED S:** TSH secreting pituitary tumors. S. Melmed (ed.) in The Pituitary by Blackwell Science, 1994.
41. **MELMED S:** Pituitary Neoplasia. In Multiple Endocrine Neoplasia. Endo and Metab Clinics of North America, Vol 23:81-92, 1994.
42. **MELMED S.** Growth hormone in Reproductive Endocrinology, E. Adashi (ed) by Raven Press, 1995.
43. **MELMED S:** Overview of growth hormone and IGF-I effects on intermediary metabolism and bone. MR Blackman, J Roth, SM Harman and JR Shapiro (eds.) in GHRH, GH, and IGF-I Basic and Clinical advances by Springer-Verlag, 1995.
44. Herman V, **MELMED S:** Acromegaly in Current Diagnosis (Vol. 9). RB Conn, WZ Borer, JW Snyder (Editors), 1995.
45. **MELMED S.** Anterior Pituitary in Current Practice of Medicine S. Korenman (ed), Philadelphia, 1996.
46. Pei L, **MELMED S:** Oncogenesis and molecular biology of pituitary tumors, S. Melmed (ed), Karger Publications, 1995.
47. **MELMED S.** Yamashita S, Yamasaki H, Fagin J, Namba H, Yamamoto H, Weber M, Morita S, Webster J, Prager D: IGF-I receptor signalling lessons from the somatotroph in Recent Progress in Hormone Research, PM Conn (Ed), Vol. 51 1996.
48. Shimon I, **MELMED S:** Anterior Pituitary Hormones in Scientific Basis of Endocrinology, PM Conn and S Melmed (Eds.), 1995.
49. Greenman Y, **MELMED S:** Somatostatin receptor subtypes in pituitary tumors in Oncogenes and molecular biology of pituitary tumors, S. Melmed (Ed), Karger, 1995.
50. Pei L, **MELMED S:** Oncogenes and tumor suppressor genes in tumorigenesis of the endocrine system in Scientific Basis of Endocrinology, PM Conn and S Melmed (Eds), 1995.
51. Herman V, **MELMED S:** Acromegaly in Current Diagnosis, RB Conn, et al (Eds) 9th Edition, 1996.
52. **MELMED S:** Molecular pathogenesis of somatotroph adenomas in Pituitary Adenomas, Elsevier, pp. 13-20, 1996.
53. Shimon I, **MELMED S:** Acromegaly: Differential diagnosis and treatment in Pituitary Disease: Diagnosis and Treatment, Wierman ME (Ed), 1997.
54. **MELMED S:** Pituitary function and neoplasia in Principles of Molecular Medicine Textbook, L Jameson (Ed), Human Press, NJ, pp 443-449, 1998.
55. **MELMED S:** Acromegaly Method in Conn's Current Therapy. R. Rakel (Ed), 1998.
56. **MELMED S:** Acromegaly in Metabolism Clinical and Experimental, 45:51-52, 1996.

57. Drange M, and **MELMED S**: IGFs in the evaluation of acromegaly. In Contemporary Endocrinology. The IGF System: Molecular Biology, Physiology, and Clinical Applications, RG Rosenfield & CT Roberts (ED), Humana Press, pp 699-720, 1999.
58. Shimon I, and **MELMED S**: Diagnosis and treatment of pituitary disease. Weitzer (ED) in Psychotherapy & Psychosomatics, 67:119-124, 1998.
59. Shimon I, **MELMED S**: Pathogenesis and molecular biology of pituitary tumors in Pituitary Tumors, Thapar K, Kovacs K, Scheithauer BW, Lloyd RV (Eds), Humana Press 1998.
60. Prezant T, **MELMED S**: Pituitary oncogenes in Epidemiology, Pathogenesis and Management of pituitary tumors (Ed) SM Webb, pp 81-93, BioScientifica Limited Bristol, UK, 1998
61. Shimon I, **MELMED S**: Pituitary tumor pathogenesis in Genetics in Endocrinology. Baxter J, Melmed S, New M (Eds), 1998.
60. Drange MR, **MELMED S**: Acromegaly: Definition and pathogenesis in Acromegaly on CD-ROM. A. Giustina (Ed), 1998.
61. Drange MR, **MELMED S**: Etiopatogenia de la Acromegalia in Libro De La Acromegalia. S. Webb (Ed), 1998.
62. Ray DW, Ren S-G, **MELMED S**: Leukemia inhibitory factor regulates proopiomelanocortin transcription in Neuroimmunomodulation: Molecular aspects, integrative systems, and clinical advances, (Ed) McCann, SM. Annals of The New York Academy of Sciences. 840:162-173, 1998.
63. Shimon I, **MELMED S**: Hypothalamic involvement in disorders of pituitary hormone secretion in Neuroendocrinology in Physiology and Medicine (Eds) Conn, PM and Freeman ME, 1998.
64. **MELMED S**, Braunstein GD: Disorders of the hypothalamus and anterior pituitary in Stein's Textbook of Internal Medicine 5th Edition. St. Louis, Mosby pp 1773-1788, 1998.
65. **MELMED S**: Pathogenesis of pituitary tumors in Advances in Pituitary Tumor Therapy. Endocrinology and Metabolism Clinics of North America, 28:1-12, 1999.
66. Auernhammer CJ, Bousquet C, Chesnokova V, **MELMED S**: Leukemia inhibitory factor-new mechanisms for ACTH regulation in Regulation of Pituitary Hormone Secretion, P Beck-Peccoz (Ed). BioScientifica Ltd., Bristol, 1999.
67. Heaney AP, **MELMED S**: Pituitary tumour transforming gene: a novel factor in pituitary tumour formation. Bailliere's Clinical Endocrinology and Metabolism. 13:367-380, 1999.
68. **MELMED S**, Auernhammer C: gp130-related cytokines in Principles of Molecular Regulation, (Eds) PM Conn and Means AR, pp 115-132, 2000.
69. **MELMED S**: Growth hormone in New World Health, Sterling Publications, 2000.
70. Shimon I, **MELMED S**: Pathogenes and molecular biology of pituitary tumors in Diagnosis and management of pituitary tumors. Thapar K, Kovacs K, Scheithauer B, Lloyd RV (Eds), Human Press, 2000.
71. Prezant T, **MELMED S**: Pathogenesis of pituitary tumors in Comprehensive Clinical of Endocrinology 3rd Edition, Harcourt by Besser & Thorner (Eds), 2001.
72. Ben-Shlomo A, **MELMED S**: Acromegaly in Neuroendocrinology, Endocrinology and Metabolism Clinics of North America Series, Klibanski A (Ed), pp. 565-583, 2001.
73. Heaney AP, **MELMED S**: Etiology of Pituitary Tumors for Pituitary Adenomas, in Pituitary Disease of Endocrine Update. Sheperd M (Ed), 2001.
74. Bonert VH, **MELMED S**: Pregnancy and Acromegaly in Pituitary Tumors in Pregnancy, Bronstein M (Ed), pp. 109-121, 2001.
75. **MELMED S**: Disorders of the anterior pituitary and hypothalamus in 15th Edition Harrison's Principles of Internal Medicine. Braunwald, Fauci, Kasper, Hauser, Longo, Jameson (Eds), pp. 2029-2052, 2001.
76. **MELMED S**: Evaluation of pituitary masses in De Groot L. and Jameson J (eds): Endocrinology, 4th Edition (Saunders) pp 282-288, 2001.
77. **MELMED S** in Neuroendocrinology and Pituitary Gland: Acromegaly in De Groot L. and Jameson J (eds): Endocrinology, 4th Edition (Saunders) pp 300-312, 2001.

78. Herman-Bonert V, **MELMED S**: Growth hormone in Reproductive Endocrinology, Surgery and Technology, Adashi, Rock and Rosenwaks (Eds), Raven Press, The Pituitary 2nd Edition, 2001.
79. Wass J, Lamberts S, **MELMED S**: Long-term treatment strategies for acromegaly in Handbook of Acromegaly, J Wass (Eds), BioScientifica, Ltd in UK, pp 79-83, 2001.
80. Wass J, **MELMED S**, Turner HE: Future areas of research in acromegaly in Handbook of Acromegaly, J Wass (Eds), BioScientifica, Ltd in UK pp. 87-89, 2001.
81. Heaney A, **MELMED S**: Molecular pathogenesis of pituitary tumors in Oxford Textbook of Endocrinology, Wass & Shalet (Eds), 2002.
82. Abbud R, **MELMED S**: SOCS: Suppressors of cytokine signaling. In The Encyclopedia of Molecular Medicine, Ed. Thomas E. Creighton, Wiley & Sons, Inc., 2002.
83. **MELMED S**: Anterior Pituitary in Williams Textbook of Endocrinology, 10th Edition, Larsen, Kronenberg, Melmed & Polonsky (Eds), Harcourt Hlth Sci, 2002.
84. **MELMED S**: Acromegaly in The Pituitary 2nd Edition, Blackwell Sciences, 2002.
85. Prezant T, **MELMED S**: Pathogenesis of pituitary tumors. Comprehensive Clinical Endocrinology, 3rd Edition, Besser M & Thorner M (Ed), 2002.
86. Greenman Y, **MELMED S**: TSH-secreting tumors in The Pituitary 2nd Edition, Blackwell Sciences 2002.
87. Bonert VH, **MELMED S**: Growth Hormone in The Pituitary 2nd Edition, Blackwell Sciences, 2002.
88. Bonert VH, **MELMED S**: Early Diagnosis and Treatment of Endocrine Disorders (Ed) Robert S. Bar, Humana Press Inc., 2002.
89. Ben-Shlomo A, **MELMED S**: Primary pharmacotherapy for acromegaly. The expanding role of octreotide II: advances in endocrinology and eye disease. Eds: Lamberts SWJ & Ghigo E. BioScientifica 2002.
90. Yu R, **MELMED S**: Pituitary oncogenes in Central and Peripheral mechanisms in pituitary disease (Eds DL Kleinberg and DR Clemmons) pp 99-118, BioScientifica Ltd, Bristol, 2002.
91. Castro AVB, **MELMED S**: Growth regulation: Clinical aspects of GHRH Encyclopedia of Hormones, Elsevier Science (USA), pp. 226-234, 2003.
92. Murray RD, **MELMED S**: Acromegaly in NORD Guide to Rare Disorders, Lippincott, Williams and Wilkins, Philadelphia, PA, 2003.
93. Murray RD, **MELMED S**: Growth Hormone Deficiency in NORD Guide to Rare Disorders, Lippincott, Williams and Wilkins, Philadelphia, PA, 2003.
94. **MELMED S**, Kleinberg DL: Anterior pituitary in Williams Textbook of Endocrinology 10th Edition, Larsen, Kronenberg, Melmed, Polonsky (Eds), Saunders Publication, pp. 177-280, 2003.
95. Murray RD, **MELMED S**: The Pituitary in Encyclopaedia of Life Sciences, 2004.
96. Heaney A, **MELMED S**: Oncogenes and tumor suppressor genes in tumorigenesis of the endocrine system in Scientific Basis of Endocrinology, PM Conn and S Melmed (Eds), 2004.
97. Shimon I, **MELMED S**: Anterior pituitary hormones in Scientific Basis of Endocrinology, PM Conn and S Melmed (Eds), 2004.
98. Ben-Shlomo A, **MELMED S**: Acromegaly, Therapy. Encyclopedia of Endocrine Diseases Vol 1, 2004, Elsevier Inc.
99. Yu R, **MELMED S**: Pituitary tumor transforming gene: an update. Kontogeorgos G, Kovacs K (eds) in Molecular Pathology of the Pituitary. Front Horm Res, Basel, Karger, 32:175-185, 2004. PMID: 15281346 DOI: 10.1159/000079044
100. **MELMED S**, Jameson JL: Disorders of the anterior pituitary and hypothalamus in 16th Edition of Harrison's Principles of Internal Medicine, Kasper, Braunwald, Fauci, Hauser, Longo, Jameson (Eds), McGraw Hill Publishing, pp 2076-2097, 2005.
101. **MELMED S**: Acromegaly in DeGroot Textbook of Endocrinology (5th Edition), 2005.
102. **MELMED S**. Evaluation of Pituitary Masses in De Groot Textbook of Endocrinology (5th Edition), 2005.

103. Heaney A, **MELMED S**: Oncogenes and tumor suppressor genes in tumorigenesis of the endocrine system. In Endocrinology: Basic and Clinical Principles, 2nd Edition (PM Conn and S Melmed, Eds), Humana Press, 2005.
104. Yu R, Hui H, **MELMED S**: Insulin secretion and action. In Endocrinology: Basic and Clinical Principles, 2nd Edition (PM Conn and S Melmed, Eds), Humana Press, 2005.
105. Donangelo I, **MELMED S**: Treatment of Acromegaly: Future. In Endocrine 2005, 28:123-8.
106. Donangelo I, **MELMED S**. Primary Medical Therapy of GH-Secreting Adenomas. In: Laws ER and Lanzino G: Transsphenoidal Surgery. Philadelphia, Elsevier, 2005.
107. Yu R, **MELMED S**: Pituitary tumor transforming gene: an update *in* Molecular Pathology of the Pituitary (Eds) Kontogeorgos G, Kovacs K. In Frontiers of Horm Res 32, pp. 175-185, 2006. Karger Publication.
108. **MELMED S**, Jameson JL: Disorders of the anterior pituitary and hypothalamus *in* Harrison's Endocrinology, J Larry Jameson (Ed), pp. 19-56, 2006.
109. Donangelo I, **MELMED S**: Molecular pathogenesis of pituitary adenomas *in* Clinical Endocrine Oncology, 2nd Edition, Ian Hay and John Wass (Eds), 2006.
110. Chesnokova V, Yu R, Ben-Shlomo A, **MELMED S**: Pituitary trophic status as a tumorigenic determinant *in* Hormonal Control of Cell Cycle, Melmed S, Rochefort H, Chanson P, Christen Y (Eds), Proceedings *in* International Workshop Fondation Ipsen, pp. 83-87, 2006.
111. **MELMED S** and Kleinberg D: Anterior Pituitary *in* Williams Textbook of Endocrinology 11th Edition, pp. 155-263, 2007.
112. **MELMED S**: Pituitary *in* ACP Medicine, Dale DC, Federman, DD (Eds). WebMD Corporation, 2008.
113. Ben-Shlomo A, **MELMED S**: Acromegaly *in* Endocrinology and Metabolism Clinics of North America, 37:101-122, 2008. PMID: PMC2697616
114. **MELMED S**, Jameson JL: Disorders of the Anterior Pituitary and Hypothalamus. 17th Edition of Harrison's Principles of Internal Medicine, Fauci, Braunwald, Kasper, Hauser, Longo, Jameson, Loscalzo (Eds), McGraw Hill Publishing, 2195-2216, 2008.
115. Snyder P and **MELMED S**: Clinically nonfunctioning pituitary masses. In De Groot and Jameson Endocrinology, 6th Edition, by Elsevier Publication, 2009.
116. **MELMED S**: Acromegaly. In De Groot and Jameson Endocrinology, Elsevier Publication 6th Edition, 2009.
117. Yu R and **MELMED S**: Current concepts in molecular pathogenesis of acromegaly *in* Acromegaly: A handbook of history, current therapy and future prospects, JAH Wass (Eds), Bioscientifica Publishing, pp. 21-39, 2009.
118. Ben-Shlomo A, Liu NA, **MELMED S**: Pathogenesis of Cushing's Disease *in* Cushing's Disease Textbook, M. Bronstein (ed), 2009.
119. Donangelo I, **MELMED S**: Molecular pathogenesis of pituitary tumors. In Oxford Textbook of Endocrinology and Diabetes, Wass J & Stewart P (Eds), 2010.
120. Yu R, **MELMED S**: Pathogenesis of Pituitary Tumors. In Neuroendocrinology Textbook, Martini L (Ed), Elsevier Publisher, 2010.
121. **MELMED S**, Ho K: Pituitary Physiology and diagnostic evaluation. In Williams Textbook of Endocrinology, 12th Edition, Elsevier, 2010.
122. **MELMED S**, Kleinberg D: Pituitary masses and tumors. In Williams Textbook of Endocrinology, 12th Edition, Elsevier, 2010.
123. Bonert VH, **MELMED S**: Growth Hormone. In The Pituitary, 3rd Edition, Elsevier Publisher, San Diego, CA, 2010.
124. Ben-Shlomo A, **MELMED S**: Regulation of the hypothalamic pituitary axis. In The Pituitary, 3rd Edition, Elsevier Publisher, San Diego, CA, 2010.
125. **MELMED S**: Acromegaly. In The Pituitary, 3rd Edition, Elsevier, San Diego, CA, 2010.
126. Greenman Y, **MELMED S**: TSH-secreting pituitary tumors. In The Pituitary, 3rd Edition, Elsevier Publisher, San Diego, CA, 2010.

127. **MELMED S**, Jameson LJ: Disorders of the anterior pituitary and hypothalamus. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J (Eds) in Harrison's Principles of Internal Medicine, 18th Edition 2010.
128. Chesnokova V, Zonis S, Ben-Shlomo A, Wawrowsky K, **MELMED S**: Molecular mechanisms of pituitary adenoma senescence. Arzt E, Bronstein M, Guitelman M (Eds) in Pituitary Today II: New Molecular, Physiological and Clinical Aspects, Front Horm Res, Basel, Karger 2010.
129. **MELMED S**. Pituitary Genetic factors in Cushings. New M, Lekarev O, Parsa A, Yuen TT, O'Malley B and Hammer GD (Eds) in Genetic Steroid Disorders, 2012.
130. Snyder PJ and **MELMED S**: Clinically non-functioning sellar masses. DeGroot LJ, Jameson JL, Kretser DD, Grossman AB, Marshall JC, Melmed S, Potts JT Jr, Weir GC (Eds) in Endocrinology: Adult and Pediatric, 7th Edition, Elsevier, 2013.
131. Parsa A, **MELMED S**: Genetic factors in Cushing Disease Pathogenesis. New MI (Ed), Lekarev O, Parsa A, Yuen TT, O'Malley B, Hammer GD (Assoc Eds) in Genetic Steroid Disorders, 2013, Elsevier.
132. **MELMED S** and Kleinberg D: Pituitary Masses and Tumors. Kronenberg HM, Melmed S, Polonsky KS, Larsen PR (Eds): in Williams Textbook of Endocrinology, 13th Edition, Elsevier, 2015.
133. **MELMED S**. Acromegaly. DeGroot LJ, Jameson JL, Kretser DD, Grossman AB, Marshall JC, Melmed S, Potts JT Jr, Weir GC (Eds) in Endocrinology: Adult and Pediatric, 7th Edition, Elsevier, 2015.
134. **MELMED S**, Jameson LJ: Hypopituitarism. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL & Loscalzo J (Eds) in Harrison's Principles of Internal Medicine 19th Edition, McGraw-Hill Publications, pp 2255-2261, 2015.
135. **MELMED S**, Jameson LJ: Anterior Pituitary Tumor Syndromes. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL & Loscalzo J (Eds) in Harrison's Principles of Internal Medicine 19th Edition, McGraw-Hill Publications, pp 2261-2274, 2015.
136. **MELMED S**, Jameson LJ: Anterior Pituitary: Physiology of Pituitary Hormones. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL & Loscalzo J (Eds) in Harrison's Principles of Internal Medicine 19th Edition, McGraw-Hill Publications, pp 401e1-401e4, 2015.
137. **MELMED S**. Hypothalamic-Pituitary Regulation. In: Conn, M.P., ed., Conn's Translational Neuroscience. San Diego: Academic Press, pp 317-331, 2017.
138. Bonert VH, **MELMED S**: Growth Hormone. In: The Pituitary, 4th Edition, Elsevier, San Diego, CA, 2017.
139. Ben-Shlomo A, **MELMED S**: Regulation of the hypothalamic pituitary axis. In: The Pituitary, 4th Edition, Elsevier, San Diego, CA, 2017.
140. Labadzhyan A, **MELMED S**: Contemporary Endocrinology Series: Plurihormonal adenomas. In: Prolactin Disorders: From Basic Science to Clinical Management. NA Tritos and A Klibanski (Eds), Springer 2018.
141. **MELMED S**: Molecular Pathogenesis of Pituitary Tumors. In: Clinical Oxford Textbook of Endocrinology & Diabetes. J Wass, P Stewart SA Amiel, M Davies (Eds), Oxford University Press, 2018.
142. **MELMED S**, Jameson JL: Hypopituitarism. Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J (Eds) in Harrison's Principles of Internal Medicine 20th Edition, McGraw-Hill Publications, 2018.
143. **MELMED S**, Jameson JL: Pituitary Tumor Syndromes. Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J (Eds) in Harrison's Principles of Internal Medicine 20th Edition, McGraw-Hill Publications, 2018.
144. **MELMED S**, Jameson JL: Physiology of Anterior Pituitary Hormones. Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J (Eds) in Harrison's Principles of Internal Medicine 20th Edition, McGraw-Hill Publications, 2018.
145. **MELMED S**, Auchus RJ, Goldfine AB, Koenig RJ, Rosen C, Larsen PR, Polonsky KS, Kronenberg HM: Principles of Endocrinology. Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, Rosen C (Eds): in Williams Textbook of Endocrinology, 14th Edition, Elsevier, 2020.

146. **MELMED S**: Pituitary Masses and Tumors. Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, Rosen C (Eds): in Williams Textbook of Endocrinology, 14th Edition, Elsevier, 2020.
147. Even-Zohar N, Armagan DM, **MELMED S**: Pituitary Stem cells. Vitamins and Hormones. In Hormones and Stem Cells (G Litwack Editor), Vol 116, pp. 1-19, Elsevier, 2021, PMID: 33752816
148. Famini P and **MELMED S**: Pituitary Apoplexy in Endocrine emergencies recognition and treatment 2nd Edition by L Loriaux and C Vanek (Editors), Contemporary Endocrinology, L Poretsky (Series Editor), Springer Nature, pp 173-208, 2021.
149. Ben-Shlomo A and **MELMED S**: Hypothalamic regulation of anterior pituitary function. In: The Pituitary, 5th Edition (S Melmed, Editor). Elsevier, pp 27-50, 2022.
150. Herman-Bonert VS and **MELMED S**: Growth hormone. In: The Pituitary, 5th Edition (S Melmed, Editor). Elsevier, pp 91-130, 2022.
151. **MELMED S**: Acromegaly. In: The Pituitary, 5th Edition (S Melmed, Editor). Elsevier, pp 449-494, 2022.
152. **MELMED S**: Acromegaly. In: DeGroot's Endocrinology: Basic Science and Clinical Practice, 8th Edition (RP Robertson, LC Giudice, A Grossman, GD Hammer, MD Jensen, GJ Kahaly, RS Swerdloff, RJ Thakkar, Editors). Elsevier, 2022.
153. **MELMED S** and JL Jameson. Physiology of anterior pituitary hormones. In: Harrison's Principles of Internal Medicine, 21st Edition (J Loscalzo, DL Kasper, DL Longo, AS Fauci, SL Hauser, and JL Jameson, Editors). McGraw-Hill, pp 2891-2895, 2022.
154. **MELMED S** and JL Jameson. Hypopituitarism. In: Harrison's Principles of Internal Medicine, 21st Edition (J Loscalzo, DL Kasper, DL Longo, AS Fauci, SL Hauser, and JL Jameson, Editors). McGraw-Hill, pp 2896-2901, 2022.
155. **MELMED S** and JL Jameson. Pituitary tumor syndromes. In: Harrison's Principles of Internal Medicine, 21st Edition (J Loscalzo, DL Kasper, DL Longo, AS Fauci, SL Hauser, and JL Jameson, Editors). McGraw-Hill, pp 2902-2917, 2022.
156. Liu NA, Parsa A, and **MELMED S**. Genetic factors in Cushing disease pathogenesis. In: Genetic Steroid Disorders, 2nd Edition (M New, B O'Malley, G Hammer, O Lekarev, A Parsa, M Zaidi, T Yuen, A Khattab, Editors). Elsevier, 2023.